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Adenosine is a neuromodulator with several functions in the central nervous system (CNS), 
such as inhibition of neuronal activity in many signaling pathways. Most of the sedating, 
anxiolytic, seizure-inhibiting and protective actions of adenosine are mediated by adenosine 
A1 receptors (A1R) on the surface of neurons and glia. Positron Emission Tomography 
(PET) is a powerful in vivo imaging tool which can be applied to investigate the 
physiologic and pathologic roles of A1R in the human brain, and to elucidate the 
mechanism of action of therapeutic drugs targeting adenosine receptors, nucleoside 
transporters and adenosine-degrading enzymes. In this Introduction, we discuss (i) 
functions of adenosine and its receptors in cerebral metabolism; (ii) radioligands for A1R 
imaging: xanthine antagonists, non-xanthine antagonists, and agonists; (iii) roles of A1R in 
health and disease, viz. sleep-wake regulation, modulation of memory retention and 
retrieval, mediating the effects of alcohol consumption, protecting neurons during ischemia 
and reperfusion, suppression of seizures, modulating neuroinflammation and limiting brain 
damage in neurodegenerative disorders. The application of PET imaging could lead to 
novel insights in these areas. Finally (iv), we discuss the application of PET in 
pharmacodynamic studies and we examine therapeutic applications of adenosine kinase 
inhibitors, e.g. in the treatment of pain, inflammation, and epilepsy. Finally we discuss the 





1.1. Sources, Regulation and Fate of Extracellular        
   Adenosine 
 
The purine nucleoside adenosine is not a classical signaling substance, as adenosine is neither 
stored nor released from vesicles. The nucleoside plays a neuromodulatory role by affecting 
the excitability of neurons that release neurotransmitters such as glutamate, gamma-amino 
butyric acid (GABA), acetylcholine and dopamine [1-12]. Adenosine is involved in 
homeostatic reduction of cellular excitability during stress and trauma via its interaction with 
receptors on the cell surface. Moreover, adenosine is involved in the regulation of synaptic 
plasticity. Balanced activation of inhibitory and facilitatory adenosine receptors modulates 
long term potentiation (e.g., in the hippocampus) [13-15]. Metabolic pathways involved in 
the formation and removal of adenosine are presented in Fig. (1). Extracellular adenosine 
may originate from intracellular adenosine - which can pass the plasma membrane via an 
equilibrative nucleoside transporter (ENT), or by hydrolysis of locally released adenine 
nucleotides such as adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine 
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monophosphate (AMP) and to a lesser extent cyclic adenosine monophosphate (cAMP). 
Production of extracellular adenosine is the result of the breakdown of such nucleotides by 
ecto-nucleotidases [16-18]. The rate-limiting step is the conversion of AMP to adenosine 
which is catalyzed by ecto-5’-nucleotidase (CD73). The biochemical and pharmacological 
properties of this enzyme have been extensively characterized [16, 19]. 5’- Nucleotidase is 
inhibited by ATP and ADP [18]. The quantititative importance of this mechanism has been 
confirmed by a kinetic characterization of the breakdown of extracellular ATP at the 
cholinergic striatal synapse [20]. Extracellular adenosine is subject to metabolic degradation 
by adenosine deaminase (ADA) which results in the formation of inosine [21]. Another route 
of adenosine inactivation is the reversible reaction catalyzed by S-adenosyl homocysteine 
(SAH) hydrolase [22]. Formation of SAH from adenosine and homocysteine is restricted 
since homocysteine levels are rate-limiting.In the brain, the SAH pathway is a quantitatively 
negligible pathway of adenosine catabolism [23]. The major route of adenosine removal 
under normal conditions is phosphorylation to AMP by adenosine kinase (AK). 
 
1.2. Classification of Adenosine Receptors 
 
The adenosine receptor (AR) family consists of the A1, A2A, A2B and A3 subtypes (A1R. 
A2AR, A2BR and A3R, respectively).A1R and A3R inhibit whereas A2AR and A2BR stimulate 
production of the second messenger, cAMP. A1R and A2AR are activated by nanomolar 
concentrations of adenosine whereas A2BR and A3R become activated only when adenosine 
levels rise into the micromolar range during inflammation, hypoxia or ischemia [24-26]. The 
four AR subtypes from rat, mouse, human and other species have been pharmacologically 
recognized, cloned, purified and expressed [27-29].  
 
1.3. Regional Distribution and Signaling of A1R 
 
The A1R is the most strongly preserved AR subtype among different animal species [28]. 
A1Rs exhibit the highest affinities for adenosine and synthetic agonists of all AR subtypes 
[30]. They are distributed throughout the body and are also highly expressed in the brain, 
especially in hippocampus, frontal cortex, thalamic nuclei, basal ganglia and dorsal horn of 
the spinal cord. Peripheral organs with high A1R expression include eye, adrenal gland, heart 
and aorta.The regional distributions of A1R in human and rodent brains are similar but not 
completely identical. In human cerebellum, A1R densities are low in contrast to rat 
cerebellum, where moderate A1R expression is noted [31-36]. Different neurons express 
different levels of A1R. In rat brain, the highest A1R immunoreactivity is observed in 
pyramidal neurons of layer 5 of the cerebral cortex, and in pyramidal cells in fields CA2 and 
CA3 of the hippocampus. In layer 5, immunoreactivity is detected in cell bodies, dendrites 




Fig. (1). Metabolic scheme showing the pathways of adenosine formation and removal. 
Enzymes involved are: 1. ATPases, 2. oxidative phosporylation (and creatine kinase), 3. 
adenylyl cyclase, 4. adenylate kinase, 5. phosphodiesterase, 6. 5’-nucleotidase, 7. adenosine 




Activation of A1Rs inhibits adenylyl cyclase, closes voltage dependent Ca
2+
 channels, and 
activates K
+
 channels. Signalling of this AR subtype occurs through Gi/o pathways in 
various cells (including neurons). As a result, the neuronal activity is suppressed [38, 39]. 
In presynaptic regions, adenosine inhibits neurotransmitter and neuropeptide release, 
including the release of glutamate, substance P and calcitonin gene related peptide [40]. In 
postsynaptic areas, adenosine abolishes sensory transmission and causes membrane 
hyperpolarisation [41,42].  
 
2. Radioligands for A1R Imaging 
 
PET is a medical imaging technique providing information on tissue biochemistry rather than 
anatomy. PET imaging has several unique properties: high sensitivity, low radiation dose, 
possibility to correct data for attenuation and scatter (thus quantitative), radioactive labeling 
of natural substances or drugs with high specific radioactivity so that these can be used as 
tracers to monitor the pharmacokinetics of the non-radioactive compounds. PET may 
therefore be applied to measure regional AR densities in the living human brain and the 
dose-dependent occupancy of cerebral AR by therapeutic drugs. A comprehensive overview 
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of PET tracers for the different AR subtypes has been presented in some recent reviews [43, 
44]. Several ligands for PET imaging of A1R have been prepared .These include xanthine 
A1R antagonists, non-xanthine A1R antagonists and A1R agonists. All compounds bind with 
nanomolar affinity to A1R. The best-characterized tracers are [
11
C] MPDX and [
18
F] CPFPX. 
Both can be applied for PET studies of cerebral A1R in humans. The long physical half life of 
18
F (109.8 min) as compared to 
11
C (20.4 min) allows longer scanning times with [
18
F] 
CPFPX than with [
11
C] MPDX. Because of this difference in half life, [
18
F] CPFPX can be 
distributed to remote imaging sites without cyclotron facilities, in contrast to [
11
C] MPDX. 
However, the radiation dose that subjects will receive after injection of [
18
F] CPFPX (300 
MBq) is greater than that of [
11
C] MPDX (300 MBq): 5.3 mSv vs. 1.05 mSv, respectively 
([45] and Ishiwata, unpublished data). Thus, multiple-injection protocols are possible with 
[
11
C] MPDX but not with [
18
F] CPFPX. Since each tracer has specific advantages and 
disadvantages, tracer selection will be based on historic interest and the facilities at one’s 
disposal rather than on clear superiority of a certain compound. Efforts to develop A1R 
ligands for PET with improved properties might focus on antagonists with reduced 
lipophilicity and improved water solubility, e.g. compounds with non-xanthine structures. 
However, the first reported example of such tracers, [
11
C] FR194921, did not produce better 
results in experimental animals than [
11
C] MPDX or [
18






Studies performed Findings References 
Xanthines     





3.0 nM (Ki) Biodistribution study in mice 
Ex vivo autoradiography 
(mice/rats) 
 
PET study in anesthetized 
monkeys 
About 57% specific binding (to A1R not A2R) 
Tracer distribution in brain reflects regional A1R density 
Decreased binding in superior colliculus after unilateral 
eye removal 
Tracer distribution in brain reflects regional A1R density 
About 50% reduction in uptake after treatment with ―cold‖ 
KF15372 
[254-256] 




1.7 nM (Ki) Biodistribution study in mice About 50% specific binding (to A1R not A2R) [257] 




4.2 nM (Ki) Biodistribution study in mice 
 
Metabolite analysis in mice 










PET study in anesthetized 
monkey 
Human PET study  
Initial brain uptake higher than EPDX and KF15372 but 
faster washout. 
Dosimetry data indicate acceptable radiation dose in 
human studies. 
Metabolites appear in plasma but brain activity is mainly 
parent at 30 min. 
Decreased binding in superior colliculus after unilateral 
eye removal. 
About 55% specific binding (to A1R not A2R). 
In animal model of dystonia, tracer binding in 
hippocampus is decreased. 
--- 
Distribution volume of tracer in brain reflects regional A1R 
density. 
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(healthy volunteers) In a cat model of stroke, losses of A1R can be detected in 
ischemic areas. 
The magnitude of these losses indicates severity of the 
insult and  
predicts subsequent complications (including mortality). 
Good brain uptake, distribution reflects regional A1R 
density. 
Tracer distribution in brain reflects regional A1R density. 
Pattern differs from that of a flow tracer or a glucose 
analog. 
Distribution volume (Logan plot) or binding potential 
(compartment  
model analysis) can be used for quantification purposes. 
 








4.4 nM (Kd 
rat) 
 
Biodistribution study in mice 
Metabolite analysis in mice 
 
Ex vivo autoradiography (rats) 
Animal PET study in rats 










Metabolite study (liver  
microsomes) 
Distribution in brain reflects regional A1R density. 
Metabolites appear in plasma but brain activity is mainly 
parent at 60 min. 
About 70% of brain uptake is specific (to A1R) and 
reversible. 
Tracer distribution in brain reflects regional A1R density 
(>90% specific). 
Brain well-visualized, bound tracer can be displaced by 
A1R antagonist. 
Tracer distribution in brain reflects regional A1R density. 
Tracer kinetics in human brain are appropriate for 
quantititative imaging. 
Distribution volume (Logan plot) or binding potential 
(compartment  
model analysis) can be used for quantification purposes. 
Simplified study protocols are possible (venous rather than 
arterial blood 
sampling, bolus-infusion or single bolus administration of 
the tracer). 
Short scanning protocols (60 min) are possible in humans. 



















Non-invasive procedure (reference tissue model) is 
suitable for 
quantification of A1R in human brain.  
Tracer is metabolized by cytochrome CYP1A2. 
Its metabolism can be inhibited by therapeutic drugs like 
fluvoxamine. 





0.8-7.9 nM  
(Kd rat, pig 
cortex) 
Ex vivo autoradiography (rats) Tracer binding is largely nonspecific. 
Thus, this ligand is not suitable for imaging purposes. 
The iodine radiolabeling results also in loss of selectivity 
for the A1R. 
[277] 
     
Non-xanthines     






2.9 nM (Ki) Ex vivo autoradiography (rats) 
 
PET study in conscious 
monkeys 
Tracer distribution in brain reflects regional A1R density. 
About 50% specific binding (to A1R not A2R). 







     
Agonists     
     
5-O-(methyl[75Se]seleno)- 
N6-cyclopentyladenosine 




No in vivo data reported [278] 







No in vivo data reported 
May bind not only to A1R but also to other AR subtypes 
[279] 





3. Physiological role of A1R and changes of A1R       
  expression in disorders of the CNS 
 
3.1 Sleep-Wake Regulation 
 
Adenosine plays an important role in the induction of sleep after prolonged wakefulness 
[47]. Prolonged wakefulness with its associated prolonged neuronal activity increases 
extracellular adenosine levels in the forebrain of conscious cats, whereas these levels 
diminish during sleep [48]. A [
18
F]CPFPX-PET study in humans has indicated that in 
addition to changes of extracellular adenosine, A1R are upregulated in cortical and 
subcortical regions of the brain after prolonged wakefulness (max. 15.3%), which suggests 
that changes of A1R expression are contributing to homeostatic sleep regulation [49]. Short 
periods of total sleep deprivation (3 or 6 h) result in increases of A1R mRNA but no 
detectable increases of A1R expression in rat brain [50]. However, longer periods of total 
sleep deprivation in rodents (12 or 24 h) are accompanied by a significant upregulation of 
A1R (up to 14%) in various brain areas [51,52].  [
3
H]Phenylisopropyladenosine (PIA, 
Figure 3) saturation binding assays have indicated that A1R densities in cortical and 
subcortical regions of rat brain are increased not only after total sleep deprivation, but also 
after 48 and 96 h of partial, rapid eye movement (REM) sleep deprivation, whereas affinity 
(Kd) values for agonist binding are not significantly altered [53]. After restriction of sleep 
and also after performance of a difficult learning task, cerebral synchronized slow wave 
activity (SWA) is enhanced during the next sleeping period, and this activity is related to 
the subsequent improvement of cognitive performance [54,55]. Activation of A1R is 
necessary for the increase of SWA. If this increase is impaired (e.g. because of knockout of 
the A1R gene) animals fail to maintain normal cognitive function.  Thus, adenosine 
appears to be an important homeostatic sleep factor, and A1Rs are involved in the regulation 
of sleep. 
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After administration of a selective A1R agonist, N6-Cyclopentyladenosine (CPA, 
Figure 3), either by the systemic or the cerebroventricular route, SWA increased in rats 
during non-REM sleep [56]. Such stimulation of A1R mimics the effect of total sleep 
deprivation in rodents. A similar effect on sleep is observed when extracellular adenosine 
levels in the mammalian brain are raised by administering inhibitors of nucleoside transport 
[57]. When levels of extracellular adenosine in the basal forebrain are raised by 
microdialysis, vigilance of rats is significantly impaired [58]. This effect on vigilance is 
completely blocked after co-administration of a selective A1R antagonist, 
8-cyclopentyltheophylline (CPT, Figure 3),  with adenosine [58].  On the other hand, 
infusion of CPT into the basal forebrain diminishes the sleeping ability (both slow-wave 
and REM sleep) of cats  [57]. Infusion of A1R antisense in the cholinergic basal forebrain 
of rats inhibits the translation of A1R mRNA, resulting in decreased non-REM sleep and 
increased wakefulness [59]. Such pharmacological experiments have provided additional 
support for the important role of A1R in sleep regulation. Agonists for this receptor usually 
promote [60-62] while antagonists diminish [60,63] sleep.  
In rat brain, prolonged wakefulness with accompanying increases of extracellular 
adenosine and stimulation of A1R increases the activity of the transcription factor 
NF-kappaB [64,65]. This transcription factor regulates expression of several modulatory 
substances, such as interleukin-1-ß and tumor necrosis factor α, which shows a diurnal 
rhythm. Some effects of adenosine on sleep homeostasis, particularly the phenomenon of 
―sleep debt‖ may be triggered via this mechanism.  
Orexinergic neurons in the lateral hypothalamus also express A1R [66]. Adenosine 
and A1R agonists inhibit activity of the hypocretin/orexin neurons in this area via A1R 
which promotes sleep [67,68]. On the other hand, blockade of A1R in such neurons causes a 
pronounced increase in wakefulness [68,69]. Adenosine reduces the frequency of action 
potentials in hypocretin/orexin neurons by depressing excitatory synaptic transmission to 
these cells. An additional mechanism involved in the sleep-promoting effects of adenosine 
may be suppression of the activity of histaminergic neurons in the tuberomammillary 
nucleus via A1R [70].  Thus, in addition to its effects in basal forebrain, adenosine 
promotes sleep by reducing the activity of orexinergic and histaminergic neurons in the 
hypothalamus [67]. 
An additional brain region involved in sleep regulation is the pontine reticular 
formation. Microinjection of the A1R agonist N6-cyclopentyladenosine (CPA) or inhibition 
of the formation of cAMP in this area increases REM sleep [71]. Another study has shown 
that administration of an A1R agonist (N6-p-sulfophenyladenosine) decreases the 
(arousal-promoting) release of the neurotransmitter acetylcholine and increases the 
recovery time from halothane anesthesia [7]. 
 Neurons in the previously mentioned brain areas are wake-active. Thus, suppression 
of their activity via stimulation of A1R promotes sleep. In contrast to the regions mentioned 
above, the lateral preoptic area of rat hypothalamus is an area with an abundance of 
sleep-active neurons. A1R agonists and the adenosine transport inhibitor 
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4-nitrobenzyl-thioinosine have opposite effects in this area as in other regions of the brain, 
i.e. they increase wakefulness rather than sleep [72]. Thus, the adenosine-mediated effects 
on the sleep-wake cycle are both neuron- and region-dependent. 
 PET may be applied to study the involvement of A1R in the regulation of human sleep. 
Increased expression of A1R in the human cortex after prolonged wakefulness has already 
been demonstrated [49]. Future PET studies could examine the effect of partial (REM) 
sleep deprivation in humans, and cerebral A1R expression in sleeping disorders like 
narcolepsy. 
 
3.2 Learning and memory 
Acute stimulation of A1R by agonists at micromolar doses has been reported to severely 
impair both the acquisition and retention of memory in various animal and in vitro models, 
such as long-term potentiation in rat hippocampal slices [73], passive avoidance retention in 
mice [74,75], working memory in a three-panel test [76], and acquisition of conditional fear 
conditioning [77] or short-term social memory in rats [78]. These cognitive deficits are 
attenuated, or abolished, when brain slices or experimental animals are pretreated with 
selective A1R antagonists such as DPCPX. Thus, activation of A1R in many regions of the 
CNS (hippocampus, ventral striatum, posterior cingulate cortex) may negatively modulate 
information processing in the brain and may impair memory retention [73-76]. Depending 
on the test setup (dose, region of administration, time of the day), acute administration of a 
selective A1R antagonist has either no effect or it can facilitate memory performance of 
rodents [75,78,79]. 
 In contrast to acute administration, chronic administration of an A1R agonist (daily i.p. 
injections of CPA during a 9-day period) results in facilitation of spatial learning and 
memory of mice tested in a Morris water maze. These improvements are probably related to 
downregulation of A1R [80].  
 However, studies of the behavioral phenotype of mice lacking A1R have indicated that 
A1R are not essential for rodent learning. Such mice show normal motor coordination but 
reduced muscle strength. Overall spontaneous motor activity is similar to that of wild-type 
controls, but activity peaks during the light/dark cycle are flattened, which is consistent 
with A1R regulating the sleep-wake rhythm. A1R
-/-
 mice show enhanced aggression and 
decreased exploratory behavior indicating increased anxiety. However, their working 
memory in five different water maze tasks is not significantly impaired. The knockouts 
have a shorter lifespan than controls (LT50 reduced from 26 to 20 months), which suggests 
that A1R play an important protective role in mammalian tissues during aging [81,82]. In a 
follow-up study which included a six-arm radial tunnel maze test, A1R
-/-
 mice were found to 
display normal spatial learning but to habituate more slowly to the test environment [83]. 
Thus, stimulation of A1R may be required for habituation, i.e. suppression of the processing 
of irrelevant information. 
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3.3 Effects of ethanol 
Various effects of alcohol consumption appear to be mediated by adenosine and A1R. 
Ethanol metabolism in the liver causes formation of acetate, which circulates in the body at 
millimolar concentrations and is finally incorporated into acetyl-coenzyme A with 
concomitant production of AMP and adenosine [84]. Acute administration of ethanol results 
also in inhibition of the facilitated diffusion of nucleosides [84,85]. The inhibitory effect is 
specific for one particular subtype of ENT (ENT1) [86,87] and can be observed both in 
cultured cells [84,85,88] and in cerebellar synaptosomes [89,90]. Thus, ethanol augments 
the rate of adenosine formation and reduces adenosine uptake. Both mechanisms may 
increase the extracellular levels of adenosine.  
Initial attempts at measuring changes of adenosine levels within the brain after 
administration of ethanol or acetate were unsuccessful, probably because it is difficult to 
homogenize tissue, or to collect adenosine, while avoiding adenosine degradation [91,92]. 
Later analytical and microdialysis studies indicated that the levels of acetate and 
extracellular adenosine in cortical areas of rat brain are significantly increased (up to 
4-fold) after administration of physiologically relevant doses of ethanol [93,94]. 
 
A functional relationship between ethanol and adenosine was suggested by the fact 
that dipyridamole, an inhibitor of ENT1, promotes ethanol-induced motor impairment 
(EIMI) [95]. Increases of EIMI were also noted after administration of the ENT inhibitor 
dilazep or the AR agonist R-PIA, whereas the AR antagonist theophylline suppressed EIMI 
[96] Several subsequent studies demonstrated that A1R agonists accentuate and A1R 
antagonists attenuate EIMI, when infused into the motor cortex [97] or striatum [98,99]. AR 
antagonists like theophylline or caffeine (Figure 3), and lipophilic AR agonists like 
cyclohexyladenosine (CHA) modulate EIMI also after systemic administration. 
Experiments in which subtype-selective AR antagonists were administered either alone or 
in combination with agonists have indicated that the A1R subtype is involved in modulation 
of EIMI, although a contribution of A2R cannot be ruled out [97,99,100]. Co-administration 
of cAMP analogs, pertussis toxin or the (R)- and (S)-enantiomers of AR agonists with 
ethanol suggested involvement of G-protein-coupled A1R and adenylate cyclase [101,102]. 
The importance of A1R was proven by the fact that A1R antisense, applied orally, 
systemically or directly into the striatum or cerebellum reduced the regional A1R density 
and antagonized EIMI, whereas a mismatch control sequence had no effect [103,104]. A1R 
in the motor cortex, striatum and cerebellum, but not in hippocampus [98] appear to affect 
EIMI via adenosine-induced decreases in glutamate release [105,106] and/or changes of 
chloride conductance via chloride channels coupled to the GABA-benzodiazepine receptor 
complex [102,107].   
Besides playing a role in EIMI, adenosine is involved in other physiological 
responses related to the consumption of ethanol. The ENT1 inhibitor dipyridamole 
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prolongs, and the AR antagonist theophylline reduces the duration of ethanol-induced sleep 
[95]. Ethanol and acetate also potentiate the anesthetic effect of sevoflurane and isoflurane 
through metabolically generated adenosine and stimulation of A1R [108-111]. In humans, 
the AR antagonist caffeine reverses most of the sedating effects of ethanol (sleepiness, lack 
of alertness, impaired memory) but not ethanol-induced dizziness [112]. A recent study in 
rodents showed that ethanol promotes non-REM sleep but does not affect REM sleep. The 
somnogenic effect of ethanol is related to adenosine inhibition of wake-promoting neurons 
in the basal forebrain via A1R. Bilateral microinjections of the selective A1R antagonist 
DPCPX in this area reduce the effect of ethanol on non-REM sleep [113]. A study in which 
ethanol was administered to mice, either alone or in combination with selective AR agonists 
and antagonists, and animals were tested for anxiety in the elevated plus-maze, has 
indicated that activation of A1R also mediates the anxiolytic effect of ethanol [114]. 
Adenosine and A1R are not only involved in the motor impairing, sleep-promoting 
and sedating effects of ethanol, but also in counteracting the negative symptoms of ethanol 
withdrawal. Withdrawal signs in rats such as tremors and audiogenically induced seizures 
are suppressed by an A1R agonist (CCPA), and this beneficial effect is blocked after 
co-administration of an A1R antagonist (DPCPX) [115]. Other negative symptoms of 
ethanol withdrawal, such as hyperexcitability [116] and increased anxiety [117,118] are also 
ameliorated upon stimulation of A1R. AR antagonists (DPCPX, caffeine) are neurotoxic 
when administered during ethanol withdrawal, particularly in female mice, and these 
neurotoxic effects are reversed by an A1R agonist (CCPA). Sex differences observed for 
neurotoxicity of A1R antagonists during ethanol withdrawal are probably related to 
N-methyl-D-aspartic acid (NMDA)-receptor-mediated downstream signaling which is more 
pronounced in females than in males [119,120].  
Observed changes of A1R densities in rodent brain during ethanol exposure appear 
to be dependent on the experimental paradigm, the radioligand which is used for binding 
assays and the brain area that is studied. Using the agonist  [
3
H]R-PIA, increases of Bmax 
without any change of Kd were noted in the cerebral cortex of rats, 15 min after 
administration of ethanol (1.5 g/kg, [96]). In a later study, the same authors noted that the 
observed increase (+ 40.7%) is transient, receptor densities returning to the control value 
within 60 minutes [121]. Chronic administration of ethanol is also accompanied by an 
increased binding (+23%) of the agonist 2-chloro-N6-cyclopentyladenosine ([
3
H] CCPA, 
Figure 3) in rat cerebral cortex. This increase persists longer than the one observed after 
acute administration. Elevated receptor densities are observed 3, 12 and 24 h after the last 
consumption of ethanol, but the ethanol effect disappears after 3 to 6 days [122]. Increased 
binding of the A1R agonist [
3
H]CHA was also noted in the cerebral cortex of mice 
following chronic administration of ethanol [123]. The increase is most pronounced after 
multiple episodes of ethanol withdrawal, and may be a compensatory inhibitory response to 
withdrawal seizures [124]. In contrast to the changes observed with A1R agonists, cortical 
binding of the A1R antagonist [
3
H]DPCPX is not affected by ethanol treatment [116,122]. 
Whereas most studies reported a transient increase of A1R agonist binding upon acute or 
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chronic administration of ethanol, one old [95] and one recent [125] study reported 
decreases of A1R expression in some brain areas of rats. Decreased A1R expression in the 
wake-promoting basal forebrain may be related to insomnia associated with ethanol 
withdrawal [125].  
Only a single PET study has examined changes of A1R expression after acute 
exposure of animals to ethanol [126]. In that study, Wistar rats were treated with a 
combination of ethanol and the AK inhibitor ABT-702, and scanned with the A1R ligand 
[
11
C] MPDX. A striking (40-45%) increase of tracer distribution volume and binding 
potential was noted in target areas such as hippocampus, striatum and cerebral cortex, 
20-90 min after treatment. Additional PET studies could be performed to study the effect of 
ethanol only, either in rodents or in the human brain. 
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3.4 Cerebral ischemia  
Levels of extracellular adenosine in the brain are dramatically increased during ischemia. In 
patients with transient ischemic attack (TIA) or stroke, a rapid rise of the plasma 
concentration of adenosine occurs in peripheral venous blood, presumably because of 
spillover from the brain, and this increase persists for days (TIA) or weeks (stroke) [127].  
Extracellular adenosine in the brain inhibits synaptic neurotransmission including the 
release of excitatory amino acids [128,129], leading to a better matching of energy demand 
and energy supply in ischemic areas and a reduction of delayed excitotoxicity [130]. 
Through A1R, adenosine promotes both the spontaneous electrical shutdown of the 
ischemic brain [131] and post-ischemic electrocortical burst suppression [132,133]. When 
levels of extracellular adenosine in mouse brain are reduced by transgenic overexpression 
of AK, postischemic cell death is increased [134]. 
The importance of A1R stimulation was also evident in studies regarding ischemic 
preconditioning. When neurons or living animals are exposed to a short period of sublethal 
ischemia, they are better protected to a subsequent serious ischemic insult. This beneficial 
effect of preconditioning disappears in the presence of an A1R antagonist like DPCPX, 
suggesting that A1R stimulation is involved [135-139]. The mechanisms underlying 
induction of rapid tolerance by a sublethal ischemic insult are not fully understood. 
Increases in protein kinase C activity, mitogen-activated protein (MAP) kinase activity, Akt 
activity, nitric oxide production and mitochondrial KATP channels may all be involved 
[135-139]. Activation of presynaptic K
+
 channels via stimulation of A1R may decrease 
evoked neurotransmitter release by hyperpolarization of the presynaptic membrane and thus 
improve resistance of the brain to ischemia.  
In various animal and in vitro models, acute administration of A1R agonists 
[140-143], inhibitors of adenosine uptake (propentofylline but not dipyridamole) [144], or 
inhibitors of AK [134] has been shown to result in protection against ischemic brain 
damage and reperfusion injury. Long-term treatment of gerbils with caffeine causes an 
upregulation of cerebral A1R (10-17%) and greater resistance of neurons to ischemia 
induced by bilateral carotid artery occlusion [145]. Increasing the binding of adenosine to 
A1R by administration of an allosteric enhancer also results in decreased brain damage after 
a hypoxic insult [146]. In contrast, acute administration of an A1R antagonist such as 
DPCPX aggravates the consequences of cerebral ischemia [141,142,147].  
Therapeutic application of A1R agonists in stroke patients may be complicated by 
the fact that such compounds can have diametrically opposite effects after chronic and 
acute administration. Acute treatment with an A1R agonist may reduce postischemic 
neuronal losses whereas chronic treatment with the same compound increases brain damage 
[142,148]. Other agonists are neuroprotective even during chronic treatment [149]. The 
underlying mechanisms are far from clear since the consequences of chronic administration 
of A1R ligands can not always be related to up- or downregulation of A1R [142]. 
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Many studies have examined changes of A1R expression in the brain of 
experimental animals after cerebral ischemia. In most studies, rapid decreases of A1R 
mRNA and protein were observed during reperfusion [150-152] but in one study, decreases 
were noted at the mRNA but not the protein level [153]. These (slightly) discrepant findings 
may be due to the fact that different models of ischemia were employed and animals were 
examined at different intervals after the ischemic insult. Some changes appear only at 
intervals greater than 24 hours. Changes of A1R expression during ischemia have been little 
examined, as opposed to changes during reperfusion. In a single study, increases of A1R 
expression (at the mRNA and protein level) were noted during bilateral carotid artery 
ligation with a return to normal values immediately after reperfusion [154]. An interesting 
study from Japan examined changes of cerebral A1R in cat brain following an ischemic 
insult, using PET and the radioligand 
11
C-MPDX. Decreases of A1R were noted, and the 
magnitude of these losses increased with increasing severity of the insult. The extent of 
11
C-MPDX binding directly after reperfusion appeared to be a sensitive predictor of 
survival and disease symptoms during the follow-up period which lasted up to 2 months 
[155,156]. 
 
3.5 Epilepsy  
Adenosine inhibits the release of excitatory neurotransmitters and suppresses cellular 
activity and energy demand. Based on this evidence, it has been proposed that adenosine is 
a powerful endogenous anticonvulsant substance [157]. In amygdala-kindled rats, 
intracerebrally administered A1R agonists, such as 2-chloroadenosine (Figure 3) and PIA, 
could indeed suppress seizures [158-162]. These substances were also effective in other 
animal models of eplilepsy, such as entorhinal cortex kindling [163], piriform cortex 
kindling [164], hippocampal kindling [162,165], caudate nucleus kindling [162], 
intrahippocampal injection of kainic acid [166], intraperitoneal injection of pilocarpine 
[167] and hypoxia-induced convulsions [168]. The location of intracerebral administration 
is probably important for the therapeutic outcome [169]. In many studies, co-administration 
of A1R antagonists was shown to result in a reduction of the anticonvulsant effect, which 
indicates that the A1R subtype is involved in the beneficial action of the agonists.  
Inhibitors of the enzyme AK can be systemically administered and can increase 
extracellular adenosine levels in metabolically active brain regions. Such compounds show 
similar anticonvulsant actions as A1R agonists but lack the undesired peripheral side effects 
of these drugs [170]. AK is regionally overexpressed in epilepsy and this overexpression 
appears to contribute to the development and progression of seizure activity [134,171,172]. 
Local administration of adenosine by implanting encapsulated myoblasts could be a 
promising strategy for long term treatment of focal epilepsy [173] 
Further evidence for the involvement of the A1R in seizure suppression was 
obtained in animal models where A1R antagonists were administered. In a cat model of 
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epilepsy (general seizures induced by intracortical injection of penicillin), the A1R 
antagonist CPT significantly prolonged the cycle period of seizures by increasing the 
duration of ictal discharge, in contrast to 7-aminobutyric acid or opioid peptides  [174]. 
Adenosine may accumulate during the ictal phase and be cleared during the interictal phase 
in status epilepticus. In a rat model of epilepsy (electrically induced seizures), secondary 
seizures were prolonged after administration of an A1R antagonist, and partial seizures were 
converted into generalized motor seizures [175]. In another rat model of epilepsy (i.p. 
administration of pilocarpine), the A1R antagonists DPCPX and 
3,7-dimethyl-1-propargylxanthine (DPMX) showed proconvulsant effects, by significantly 
reducing the latency to develop status epilepticus [167]. Theophylline also lowered the 
seizure threshold and prolonged hyperthermia-induced seizures in juvenile rats [176]. Using 
a selective A1R antagonist (CPT), evidence was obtained that the inhibitory effect of low 
frequency stimulation of the perforant path on kindling acquisition in rats is mediated by 
stimulation of A1R [177]. 
Changes of cerebral A1R densities have been assessed both in animal models of 
epilepsy and in human brain post mortem. In a rat model of acute general seizure (i.p. 
injection of a convulsive dose of bicuculline), a widespread increase of A1R (
3
H-CHA 
binding) was noted, which was particularly evident in hippocampus, amygdala, substantia 
nigra and septum [178]. In a mouse model of general seizure (pentylentetrazol-induced 
convulsion) [179], A1R were upregulated in most brain areas but downregulated in the basal 
ganglia [180]. In tissue samples acquired from patients with temporal lobe epilepsy, a 48% 
increase of A1R density was observed in neocortex as compared to control samples from 
non-epileptic subjects [181]. 
However, in another study on human temporal lobe epilepsy, A1R binding in 
temporal cortex was found to be reduced compared to normal postmortem controls [182]. A 
15% decline of A1R density was also noted in the basal ganglia and thalamic nuclei of 
genetic absence epilepsy rats from Strasbourg compared to wild-type littermates [183]. 
Even greater losses of A1R were noted in the hippocampus and cerebral cortex of 
kainate-treated, hippocampus-kindled and amygdala-kindled rats, animal models of chronic 
epilepsy [184-187]. 
These conflicting results (either an upregulation or downregulation of A1R) may be 
related to differences in the experimental setup in animal models and differences in patient 
selection in human studies. An acute seizure, or a limited number of seizures may be 
accompanied by upregulation of A1R, or increased coupling of A1R to G-proteins 
[188,189], as a protective mechanism enhancing the anticonvulsant effect of endogenous 
adenosine. However, chronic seizures may cause a significant death of neurons with 
accompanying losses of A1R. The effects of partial and general seizures may also be 
different and the age (or developmental stage) of the subjects may affect the response of 
A1R to kindling [178,190].  
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3.6 Traumatic brain injury 
Studies in A1R knockout mice have confirmed that this subtype plays an important role in 
suppressing neuronal hyperactivity. When normal and A1R knockout mice were subjected 
to controlled cortical impact – an animal model of traumatic brain injury (TBI) - seizure 
scores were much higher in the knockouts and only the knockout animals developed lethal 
status epilepticus [191]. Similarly, unilateral hippocampal kainate injection caused 
non-convulsive status epilepticus in wild-type mice but severe convulsions and subsequent 
death of the animals in A1R knockouts [192]. The authors concluded that activation of A1R 
by adenosine is crucial in keeping an epileptic focus localized. Status epilepticus results in 
widespread adenosine release throughout the brain and suppression of the excitability of 
neurons remote from the epileptic focus via stimulation of A1R. In A1R knockout mice, this 
protective mechanism is lacking, so that severe convulsions and lethal status epilepticus can 
develop  [192]. In another animal study on mild TBI, A1R knockout mice were shown to 
display a 20-50% enhanced microglial response compared to their wild-type littermates. 
Moreover, stimulation of A1R in BV-2 (immortalized mouse microglia) cells inhibited 
microglial proliferation [193]. Thus, A1Rs appear to play an anti-inflammatory role in 
TBI-induced neuroinflammation.  
To the best of our knowledge, no PET studies on changes of A1R expression in 
epileptic patients or in animal models of epilepsy and TBI have been performed. Thus, 
there is considerable opportunity for imaging studies in this area. 
 
3.7 Neuroinflammation 
Besides its well-known function as an inhibitor of neuronal overactivity and its 
involvement in the regulation of sleep, adenosine has been proposed to act as an 
endogenous anti-inflammatory agent [194]. In the CNS, A1Rs are expressed not only on 
neurons but also on glia [195]. A1R stimulation in microglia, the endogenous immune cells 
of the brain, may have both pro- and anti-inflammatory effects, depending on the presence 
or absence of other factors in the environment, such as phorbol 12-myristate 13-acetate 
[196]. An early study reported that simultaneous activation of both A1R and A2AR 
stimulates microglial proliferation, whereas selective A1R or A2AR agonists when applied 
alone have no effect [195]. However, later studies have indicated that in most situations, 
A1R agonists suppress neuroinflammation. 
In cultured astrocytes, CCPA enhanced the release of nerve growth factor [197], a 
compound which is essential for neuronal protection and a suppressor of 
neuroinflammation within the specific environment of the brain [198]. In plasmacytoid 
dendritic cells, adenosine has been suggested to play a dual role: first, chemotaxis to the site 
of inflammation is stimulated via A1R, then, the extent of the inflammatory response is 
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limited by inhibition of the production of several cytokines such as interleukin-6, 
interleukin-12 and interferon-α [199].  
The importance of A1R in controlling neuroinflammation was highlighted by 
studies of experimental allergic encephalomyelitis (EAE). Mice lacking A1R developed a 
much more severe, progressive-relapsing form of EAE than their wild-type littermates. 
Reduced densities of A1R in microglia of wild-type mice were observed during the 
neuro-inflammatory phase of EAE. Upregulation of A1R by treatment of normal mice with 
caffeine reduces EAE severity, and this beneficial effect of caffeine can be enhanced by 
concomitant administration of an A1R agonist [200]. In a rat model of neuroinflammation 
(EAE induced by guinea pig spinal cord homogenates), chronic caffeine treatment results in 
up-regulation of A1R and attenuation of EAE pathology [201]. Experimentally induced 
neuroinflammation by chronic infusion of lipopolysaccharide (LPS) into the fourth 
ventricle of young rats, and natural microglia activation in aged rats are also attenuated 
after treatment of animals with caffeine [202]. In contrast to EAE (an animal model of 
chronic neuro-inflammation which is associated with a downregulation of A1R), acute 
inflammation of mouse brain after administration of LPS leads to increased A1R expression 
in cortical areas and this response is dependent on the transcription factor NF-kappaB 
[203].An interesting study examined the role of A1R in brain tumors. Gliomas do not 
consist only of tumor cells but to a large extent (up to 30%) also of microglia and 
macrophages. Microglial cells accumulate particularly at the tumor rim. In the tumor 
environment, microglia acquires a different phenotype which is associated with expression 
of matrix metalloprotease II (MMP2). After acquisition of this novel phenotype, the 
microglial cells do not suppress but can actually promote tumor growth and invasion since 
these processes are MMP2-dependent. Experimental glioblastomas grew more vigorously 
and were associated with larger numbers of microglial cells in A1R knockout mice than in 
wild-type mice. In wild-type animals, A1R were up-regulated in microglia in contact with 
tumor cells but not in the rest of the brain. When glioma and microglia cells were cultured 
together in vitro, A1R agonists suppressed the growth of tumor cells, but in the absence of 
microglia, the same compounds stimulated tumor growth. Thus, adenosine attenuates 
glioblastoma growth, acting through microglial A1R [204]. 
 
Changes in cerebral A1R density caused by glioma invasion have been examined 
with the tracer [
18
F] CPFPX and PET, both in an animal model (F98 glioma-bearing rats) 
and in a patient with recurrent glioblastoma multiforme. In the animal model, A1R were 
also quantified by in vitro and in vivo autoradiography and immunohistochemical analysis. 
A1R were shown to be upregulated (by 36 to 46%) in a zone directly surrounding the tumor, 
and to be localized in activated astrocytes [205]. It would be interesting to study changes of 
A1R expression with microPET in animal models of neuroinflammation (e.g., the EAE 
model, the LPS model, or virally induced encephalitis). Such studies have not yet been 
reported.   
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3.8 Human diseases of the CNS  
3.8.1Alzheimer’s disease (AD) 
Since A1R signaling can be neuroprotective, many investigators examined changes of 
regional A1R density in human brain in neurodegenerative disorders. Initial 
autoradiographic studies were focused on AD and the hippocampus, a brain region involved 
in memory. A significant loss of A1R was observed in the CA1 (-47%) and dentate gyrus 
molecular layers (-46%) of the hippocampus but not in the CA3 [206]. Another study 
reported 40-60% decreases in all areas of the hippocampus, the most striking losses 
occurring in the molecular layer of the dentate gyrus [207]. Still another investigation 
reported substantial decreases in the dentate gyrus but A1R densities close to normal in CA1 
and CA3 [208]. The former two investigations used the A1R agonist [
3
H] CHA whereas the 
last study employed the antagonist ligand [
3
H] CPDPX.  
Binding of an A1R agonist ([
3
H] R-PIA) and antagonist ([
3
H] CPDPX) in the AD 
hippocampus were later directly compared. Both ligands detected prominent losses of A1R 
in the dentate gyrus. Decreased agonist binding was observed in CA1 and outer layers of 
the parahippocampal gyrus, whereas losses of antagonist binding were noted in the 
subiculum and CA3. These decreases reflected reductions of receptor number (Bmax) rather 
than reductions of the affinity (KD) of A1R for the radioligands [209].In the striatum of AD 
patients, 30-36% losses of A1R were noted both in the caudate nucleus and putamen, and 
these losses appeared to parallel the decrease of choline acetyl transferase [210].  
An immunohistochemical study from Spain showed that A1R are redistributed in 
the hippocampus and cerebral cortex of AD patients in comparison to age-matched controls. 
A1R accumulate in degenerating neurons and are co-localized with ß-amyloid in senile 
plaques and with tau in neurons with tau deposition. Studies in the human neuroblastoma 
cell line SH-SY5Y indicated that A1R stimulation increases the production of soluble forms 
of amyloid precursor protein, and the phosphorylation and translocation of tau to the 
cytoskeleton. By inhibiting the deposition of amyloid and enhancing the translocation of tau, 
A1R stimulation may slow down the process of neurodegeneration [211].  
An upregulation of A1R was detected in the frontal cortex of AD patients (both at 
early and advanced stages of the disease), using quantitative autoradiography and the 
radioligand [
3
H]DPCPX [212]. However, a PET study in AD patients and elderly normal 
subjects indicated significant decreases of the binding potential of [
11
C]MPDX in the 
temporal and medial temporal cortices and thalamus of the patients with no significant 
change in other areas of the brain [213] (Figure 4). Discrepant findings in human studies 
may be related to the facts that different patient groups were selected (early vs. late onset 
AD), different brain regions were examined, and different techniques were used for 
quantification (immunohistochemistry, ligand binding). Moreover, a transient upregulation 
of A1R may be followed by an eventual receptor loss. 
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3.8.2 Pick’s and Creutzfeld-Jakob disease 
In the frontal cortex of individuals with Pick’s [214] and Creutzfeldt-Jakob [215] disease, 
similar increases of A1R density were noted as in patients with AD, using quantitative 
autoradiography and [
3
H]DPCPX. No PET studies with [
11
C] MPDX or [
18
F] CPFPX in 
such patients have been reported.   
 
3.8.3 Multiple sclerosis (MS) 
Several studies have reported changes of AR signaling in patients with MS.  Plasma levels 
of TNF-α in such patients are significantly higher and levels of adenosine are significantly 
lower than in control subjects. Stimulation of peripheral blood mononuclear cells (PBMC) 
with a selective A1R agonist (R-PIA) inhibits the mitogen-stimulated production of TNF-α 
in healthy subjects but not in MS patients, whereas the opposite is observed for the 
mitogen-stimulated production of interleukin-6 [216]. A1R densities in PBMC and in brain 
tissue from MS-patients are significantly decreased (by 53% and 49%, respectively) 
compared to age-matched controls [217]. Thus, both A1R densities and the coupling of A1R 
to cytokine signaling systems appear to be altered in MS. However, no PET studies with 
A1R ligands have been performed in this patient group. 
 
3.8.4 Parkinson’s disease 
In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease, 
the drug paeoniflorin proved capable of reducing neurodegeneration and inhibiting 
neuroinflammation by activation of A1R [218]. Thus, modulation of neuroinflammation via 
A1R may be a novel approach towards treatment of neurodegenerative disease. 
Deep brain stimulation (DBS) is frequently applied for the treatment of movement 
disorders and may also benefit individuals with psychiatric disease. Recently, it was shown 
that the mechanism underlying the beneficial effect of DBS is a local release of ATP which 
is extracellularly metabolized to adenosine and suppresses tremor via A1R. The effect of 
DBS can be mimicked by intrathalamic infusion of A1R agonists. On the other hand, AR 










A partial loss of A1R during birth and a corresponding reduction of the control of dopamine 
activity in later life has been proposed to play a role in the inhibitory deficit in 
schizophrenia [220,221]. Association between a single nucleotide polymorphism of the A1R 
gene (rs3766553) and schizophrenia was indeed noted in a Japanese population [222]. PET 
studies of cerebral A1R in patients with schizophrenia have not yet been performed. 
 
4. Pharmacodynamic studies 
4.1 A1R (ant) agonists 
PET has important applications in the study of pharmacodynamics, i.e. assessment of the 
effects of drugs in the healthy and diseased body, including their mechanisms of action and 
the relationship between drug concentration and effect. During the development of CNS 
drugs, PET is often used to measure the dose-dependent occupancy of target receptors in 
the human brain by a non-radioactive test compound. PET is also capable of measuring the 
metabolic response of tissues to treatment quantitatively, repeatedly and noninvasively, 
both in experimental animals and humans. 
 Only a few PET studies regarding A1R occupancy by cold antagonists have been 
reported in the literature. An interesting paper from Germany showed that the binding of 
18
F-CPFPX in rat brain is reduced after treatment of animals with caffeine, shortly before 
injection of the tracer. At a dose of 4 mg/kg, corresponding to consumption of three to four 
cups of coffee by a human being, tracer binding was strongly (ca. 50%) suppressed, 
suggesting ~70% receptor occupancy [223]. Another study showed that 
18
F-CPFPX bound 
to A1R in human brain can be dose-dependently displaced by injecting non-radioactive 
CPFPX [224]. A microPET study from our own group has indicated that A1R in rat brain 
are almost completely occupied after  administration of DPCPX (3 mg/kg, i.p.), 20 min 




Thus, the dose-dependent occupancy of A1R in the brain by test drugs may be assessed by 
PET. Dose-dependent effects of A1R agonists (or AK inhibitors, see 4.2) on organ 
metabolism could be assessed as well, using the radiolabeled glucose analog [
18
F]FDG, but 
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4.2 AK inhibitors 
AK regulates intra- and extracellular adenosine concentrations by phosphorylation of 
adenosine to AMP. Although ADA also removes adenosine by converting it to inosine, the 
reaction catalyzed by AK is the most important pathway of adenosine removal under 
physiological conditions [225]. Since the major adenosine-specific nucleoside carrier acts 
as a non-concentrative, bi-directional, facilitated diffusion transporter, adenosine transport 
is driven by the concentration gradient across the cell membrane. Inhibition of AK raises 
intracellular adenosine, diminishes the concentration gradient and decreases the cellular 
uptake of adenosine, resulting in increased extracellular adenosine concentrations, 
particular under pathophysiological conditions and in tissues or brain regions where the 
formation of adenosine is increased by net catabolism of ATP [226-228]. An in vivo study 
in rats has shown that AK inhibitors (AKIs) augment the increases of extracellular 
adenosine during excitotoxic insults in the striatum but do not affect striatal adenosine 
levels in vehicle-treated controls [228]. Thus, AKIs represent a strategy for potentiating the 
protective actions of endogenous adenosine during tissue trauma [229]. This therapeutic 
approach may be advantageous in cases where not a single subtype (e.g., A1R) but rather a 
multiplicity of AR subtypes should be stimulated for the beneficial effect [230].   
Three applications of AKIs have been proposed. First, intrathecally administered AR 
agonists [231-233] and AKIs [232-234] have antinociceptive effects in experimental 
animals. These effects are counteracted by selective A1R antagonists but not by A2AR 
antagonists suggesting involvement of A1R stimulation [228,232,235,236]. Novel AKIs 
such as ABT-702 and A-286501 can also be given subcutaneously or orally and are then 
effective in animal models of acute, inflammatory and neuropathic pain [235,237-239]. 
Substantial interest in the use of AKIs was raised by the fact that these compounds can be 
equally effective as morphine for the suppression of pain but show less potential to develop 
tolerance [238,240,241]. The use of AKIs rather than AR agonists allows an adequate 
separation between antinociceptive and motor-impairing effects [242]. Second, AR agonists 
and AKIs have shown anti-inflammatory efficacy in various animal models of acute and 
chronic inflammation [238,239,243-248]. A third potential application of AKIs is in the 
treatment of epilepsy. These compounds suppress seizures in rodent models, such as the 
bicuculline-induced seizure [249] and the maximal electroshock [170,250,251] model, 
presumably via an interaction of adenosine with cerebral A1R. For that reason and because 
upregulation of the enzyme AK is involved in epileptogenesis [171], AKIs are considered 
promising anticonvulsants [170,252,253]. 
If a ligand could be developed of which the binding is sensitive to competition by 
endogenous adenosine, PET imaging could be applied to assess changes of extracellular 





The purine nucleoside adenosine and its A1R are implied in many physiological functions, 
such as regulation of the sleep-wake cycle, aggression, and anxiety, habituation of animals 
to a novel environment, protection of cells against the negative consequences of hypoxia 
and ischemia. Adenosinergic signaling is also implied in ethanol-induced motor impairment, 
and withdrawal symptoms after ethanol abuse. Stimulation of A1R has anticonvulsant and 
anti-inflammatory actions. Changes of A1R expression have been noted in animal models of 
epilepsy, the micro-environment of brain tumors, and various diseases of the human CNS 
such as AD, Pick’s disease, Creutzfeld-Jakob disease, MS and schizophrenia. Since 
appropriate ligands for PET imaging of A1R are now available, PET can be applied to 
elucidate the role of A1R in the normal and diseased human brain and to study the 
pharmacodynamics of A1R agonists and AKI.    
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6. Aims and outline of the thesis 
 
The aim of this thesis is to apply PET imaging to measure therapy-related occupancy and 
disease-induced changes of expression of adenosine A1 receptors in the (rodent) brain. We 
used the radiolabeled xanthine [
11
C]-MPDX as tracer for evaluation of drug occupancy.  
Changes of A1R expression were examined in a rodent encephalitis model. 
 
Chapter 1: The initial chapter is a general introduction and literature review concerning 
PET imaging of adenosine A1 receptors and the function of these binding sites in health and 
disease.  
 
Chapter 2: The following chapter was a pilot study validating the use of [
11
C]-MPDX for 
quantitative microPET studies of cerebral A1R in rodents. A regional distribution of 
radioactivity was observed which corresponded closely to regional densities of adenosine 
A1 receptors known from autoradiography. Tracer binding was blocked by the selective A1R 
antagonist DPCPX. However, raising extracellular adenosine by pretreating rats with 
ethanol and the adenosine kinase inhibitor ABT-702 did not result in measurable 




Chapter 3:. A1R agonists or adenosine kinase inhibitors may be beneficial in the treatment of 
neurodegenerative diseases, epilepsy, inflammation and various forms of pain. By using PET 
it is possible to measure the fraction of receptor populations which is occupied by cold 
(non-radioactive) drugs in the living brain. Thus, occupancy of a target receptor can be 
related  to the intensity of the  therapeutic effect or to unwanted side effects. In chapter 4 
we evaluated if [
11
C]-MPDX and PET can be used  to assess A1R occupancy in the rodent 
brain by a non-radioactive agonist (N
6
-cyclopentyladenosine) and antagonist (caffeine). 
 
Chapter 4: Adenosine A1 receptors are implied in modulation of neuroinflammation. 
Upregulation of A1Rs  may also have neuroprotective properties. In chapter 4 we applied  
PET and [
11
C] MPDX to quantify changes of A1R expression in rat brain as a consequence 
of herpes simplex virus-induced encephalitis. We also performed a qualitative 
immunohistochemistry study of A1R in the same animal model. 
 
Chapter 5: With increasing prevalence of brain disorders there is an increasing demand for 
CNS drugs, but many potential candidates fail to cross the blood-brain barrier (BBB). Thus, 
there is a need to modulate BBB permeability and facilitate the entry of therapeutic drugs. 
Stimulation of adenosine A1 and A2A receptors may be possible strategy to reach this aim. 
We attempted to develop a PET assay which can assess changes in blood-brain-barrier 
permeability and can be used to examine the effects of permeability-modulating drugs. Two 
hydrophilic tracers (a CXCR4 antagonist and dopamine agonist) were used in this attempt.  
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Chapter 6 summarizes the findings of the studies reported in chapters 2 to 5. The final 
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Chapter II 
 
Small-Animal PET Study of Adenosine A1 
Receptors in Rat Brain: Blocking Receptors and 
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Abstract 
Activation of adenosine A1 receptors (A1R) in the brain causes sedation, reduces anxiety, 
inhibits seizures and promotes neuroprotection. Cerebral A1R can be visualized and 
apparent receptor densities estimated using 8-dicyclopropyl-methyl-1-[
11
C] 
methyl-3-propyl-xanthine (MPDX) and PET. We tested whether MPDX can be employed 
for quantitative studies of cerebral A1R in rodents. MPDX was injected (i.v.) into 
isoflurane-anesthetized male Wistar rats. Uptake of radioactivity in the CNS was 
continuously monitored, using a microPET Focus 220 camera. A cannula in a femoral 
artery was used for blood sampling. Three groups of animals were studied (1) controls (i.p. 
injection of saline); (2) pretreated with the A1R antagonist DPCPX (1 mg, i.p.); (3) 
pretreated with a 20% solution of ethanol (4 g/kg body weight) in saline plus the adenosine 
kinase inhibitor ABT-702 (1 mg, both i.p.). Treatment 2 results in occupancy of cerebral 
A1R by non-radioactive DPCPX, whereas treatment 3 is known to result in a large increase 
of extracellular adenosine. In groups 1 and 3, the brain was clearly visualized. High uptake 
of the tracer was noted in striatum, hippocampus and cerebellum. In group 2, tracer uptake 
was strongly suppressed and regional differences were abolished. Treatment 3 resulted in an 
unexpected 40-45% increase of the cerebral uptake of MPDX as indicated by increases of 
PET-SUV, distribution volume from Logan plot, binding potential from 2-tissue 
compartment model fit, and SUV from a biodistribution study performed after the PET scan. 
The partition coefficient of the tracer (K1/k2 from 2-tissue compartment model fit) was not 
altered under the study conditions. In conclusion: MPDX shows a regional distribution in 
rat brain consistent with binding to A1R. Tracer binding is blocked by the selective A1R 
antagonist DPCPX. Pretreatment of animals with ethanol and adenosine kinase inhibitor 
causes a significant increase of MPDX uptake. This increase appears to reflect an increased 
binding potential of A1R rather than altered delivery of MPDX to the brain. 
 
Key Words: receptors; adenosine A1; adenosine kinase inhibitor; brain; positron emission 
tomography (PET); ethanol 
 
2.1 Introduction 
  The adenosine receptor (R) family consists of the A1, A2A, A2B and A3 subtypes. These are 
members of the larger P1 family of seven transmembrane purinergic receptors. A1 and A3R 
inhibit whereas A2A and A2B stimulate production of the second messenger, cAMP. A1R and 
A2AR are activated by nanomolar concentrations of adenosine whereas A2B and A3R 
become activated only when adenosine levels rise into the micromolar range during periods 
of inflammation, hypoxia or ischemia. [1-3].  
A1Rs are highly expressed and extensively distributed in various regions of the human 
brain such as the hippocampus, cerebral cortex, thalamic nuclei, and basal ganglia (4, 5). In 
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the central nervous system, adenosine acts as an endogenous modulator of neurotransmission 
(6), a neuroprotectant (7), and an anticonvulsant (8). Its neuroprotective action is mediated 
via A1R and may be associated with inhibition of the release of excitatory neurotransmitters, 
hyperpolarization of neurons, and inhibition of Ca
2+
 channels (9). Adenosine acts also as an 
analgesic, by affecting nociceptive afferent and transmission neurons via A1R (10). A1R 
agonists usually stimulate (11), whereas A1R antagonists diminish, sleep (12). Thus, such 
compounds may be therapeutically useful. Yet, A1R agonists have failed to undergo 
successful clinical development because of dose-limiting cardiovascular side effects. 
Adenosine kinase inhibitors (AKIs) represent an alternative treatment strategy. 
Adenosine kinase (AK) catalyzes a phosphorylation reaction, converting adenosine to 
adenosine monophosphate (13, 14). The inhibition of AK decreases the cellular reuptake of 
adenosine, resulting in increased local adenosine concentrations (14). The feasibility of 
raising adenosine availability in the central nervous system by inhibiting AK has been 
demonstrated in hippocampal and spinal cord slices (15) and by in vivo studies on 
extracellular adenosine in rat striatum, which was increased up to 10-fold (16).The 
psychoactive drug ethanol also raises extracellular levels of adenosine in the brain (up to 
4-fold (17)) by augmenting the rate of adenosine formation (18) and inhibiting adenosine 
uptake via nucleoside transporters (18–20).The anxiolytic, sedating, and motor-impairing 
effects of ethanol are related to its interaction with adenosinergic signaling.PET with a 
radiolabeled A1R ligand may allow study of the involvement of A1R in the pathophysiology 
of disease, the response of the A1R population to therapy, and assessment of the occupancy 
of A1R by therapeutic drugs. Several positron emitting A1R ligands have been prepared for 





C-MPDX) (21) and 
18
F-8-cyclopentyl-3-(3-fluoropropyl)-1-propyl- 
xanthine (5). Both ligands bind with high affinity and selectivity to A1R in vivo (Ki and Kd 
values, 3.0 and 4.4 nM, respectively). 
Because small-animal PET studies with [
11
C]-MPDX had not been performed 
previously, we tested this ligand for quantitative small-animal PET studies in rodents with 
the intention of later using this technique for the assessment of changes of A1R density in 
rodent models of human disease. In addition, we examined the impact of raised levels of 








    Ethanol and triethylamine were purchased from Merck. The adenosine A1R 
antagonist 1, 3-dipropyl-8-cyclopentylxanthine (DPCPX) was a product of Sigma, and the 
potent adenosine kinase inhibitor 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3- 
yl) pyrido [2, 3-d] pyrimidine dihydrochloride (ABT-702) was obtained from Tocris. Stock  
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solutions of DPCPX and ABT-702 were prepared in dimethyl sulfoxide. The radioligand 
[
11
C]-MPDX was prepared by reaction of 
11
C-methyl iodide with the appropriate 
1-N-desmethyl precursor. Briefly, 
11
C-methyl iodide was trapped in 0.3 mL of 
N,Ndimethylformamide containing 1 mg of 1-N-desmethyl precursor and 5 mL of NaOH 
and was heated at 120ºC for 5 min. After 1.0 mL of 0.1 M HCl had been added, the solution 
was loaded onto a high-performance liquid chromatography column (Econosphere, C18, 5 
mm[Altech]; 10 · 250 mm) and eluted with a mixture of 0.1 M NaH2PO4 and ethanol (70/30) 




were collected. Retention 
time of [
11
C]-MPDX was 14 min. The decay-corrected radiochemical yield was 35% ± 5% 
(based on 
11
C-methyl iodide), the specific radioactivity was greater than 11 TBq/mmol at the 
moment of injection, and the radiochemical purity was greater than 98%. 
 
2.2.2 Animal Model 
 
The animal experiments were performed by licensed investigators in compliance with the 
Law on Animal Experiments of The Netherlands. The protocol was approved by the 
Committee on Animal Ethics of the University of Groningen. Male Wistar rats were 
maintained at a 12-h light/12-h dark regime and were fed standard laboratory chow ad 
libitum (body weights are provided in Table 1).  
 
Table 1. Animal data 
Group Body weight (g) Injected  
dose (MBq) 






Control (n = 5) 299 ± 8 24 ± 10 2.2 ± 0.9 1.02 ± 0.02 




302 ± 16 34 ± 11 3.1 ± 1.0 1.02 ± 0.03 
Metabolite 
analysis (n=6) 
314 ± 14 20 ± 12 1.8 ± 1.1 - 
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2.2.3 Small-Animal PET Scanning 
 
In most experiments, 2 rats were scanned simultaneously, using a Focus 220 microPET 
camera (Siemens-Concorde). Animals were anesthetized with a mixture of isoflurane/air min 
(inhalation anesthesia, 5% ratio during induction, later reduced to 2%). A cannula was placed 
in a femoral artery for blood sampling. Rats were under anesthesia for 30–40 min before 
tracer injection (time required for cannulation and transmission scan). The tracer 
([
11
C]-MPDX) was injected through the penile vein (injected dose is given in Table 1). A 
list-mode protocol was used (76 min, brain in the field of view). Scanning was started during 
injection of radioactivity in the lower rat; the upper animal was injected 16 min later. The 
animal that was injected last was also anesthetized at a later moment. Thus, the duration of 
anesthesia was similar in all study groups. A series of blood samples (14 samples; volume, 
0.10–0.15 mL) was drawn, initially in rapid succession (every 15 s) and later at longer 
intervals (≤30 min). Plasma was acquired from these samples by short centrifugation 
(Eppendorf centrifuge, 5 min at 13,000 rpm). Radioactivity in 25 uL of plasma was counted 
and used as an arterial input function. For examination of the specificity of tracer binding, 5 
animals were pretreated by intraperitoneal injection of DPCPX (1 mg, in 0.3 mL of dimethyl 
sulfoxide, 15–20 min before injection of the tracer). For examination of the impact of raised 
levels of extracellular adenosine on [
11
C]-MPDX binding, 5 other rats received ethanol (2 mL 
of a 20% solution in saline intraperitoneally) and the AKI ABT-702 (1 mg, in 0.3 mL of 
dimethyl sulfoxide intraperitoneally).Both ethanol and ABT-702 were administered 15–20 
min before injection of [
11
C]-MPDX. Control animals (n = 5) received saline only. The 
ethanol dose that we administered corresponds to substantial consumption of alcohol in 
humans (about six 0.33-L bottles of normal beer containing 5% alcohol). List-mode data 
were reframed into a dynamic sequence of 8 x 30, 3 x 60, 2 x 120, 2 x 180, 3 x 300, 1 x 
480, 2 x 600, and 1 x 960 s frames. The data were reconstructed per time frame using an 
iterative reconstruction algorithm (attenuation-weighted 2-dimensional ordered-subset 
expectation maximization, provided by Siemens; 4 iterations, 16 subsets; zoom factor, 2). 
The final datasets consisted of 95 slices, with a slice thickness of 0.8 mm and an inplane 
image matrix of 128 x 128 pixels of size 1 x 1 mm. Datasets were fully corrected for random 
coincidences, scatter, and attenuation. A separate transmission scan (duration, 515 s) was 
acquired for attenuation correction. That scan was made before the emission scan. Images 
were smoothed with a gaussian filter (1.35 mm in both directions). 
 
2.2.4 Small-Animal PET Data Analysis 
 
Three-dimensional regions of interest (ROIs) were manually drawn around the entire brain. 
Time–activity curves and volumes (cm3) for the ROIs were calculated, using standard 
software (Asi-Pro, version 6.2.5.0; Siemens-Concorde). PET standardized uptake values 
(SUVs) for brain radioactivity were calculated, using measured body weights and injected 
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doses and assuming a specific gravity of 1 g/mL for brain tissue and blood plasma. Dynamic 
PET data were analyzed using plasma radioactivity from arterial blood samples as an input 
function and a graphical method according to Logan (22). Because [
11
C]-MPDX proved to be 
rapidly cleared but slowly metabolized, no metabolite correction of the input function was 
performed. The error introduced by this procedure (overestimation of the true plasma input) 
is 10.0% and identical in all study groups; thus, we concluded that metabolite correction 
could be omitted. Software routines for MatLab 7. (The MathWorks), written by Dr. Antoon 
T.M. Willemsen (University Medical Center Groningen), were used for curve fitting.The 
Logan fit was started at 10 min. The cerebral distribution volume (VT) of the tracer was 
estimated from the Logan plot.The dynamic PET data were also analyzed using the same 
input function and software routines, a 2-tissue-compartment model (2TCM), and a fixed 
blood volume of 3.6%. The partition coefficient (K1/k2) and nondisplaceable binding 
potential (BPND) (k3/k4) of [
11
C]-MPDX were estimated from the model fit. Similar methods 
were used previously by Kimura et al. (23) for quantification of A1R in the human brain. 
However, A1Rs are significantly expressed in rat cerebellum, in contrast to human 
cerebellum, in which A1R density is negligible. Therefore, the cerebellum cannot be used as a 
reference region in small-animal PET studies of the rodent brain. 
 
2.2.5 Biodistribution Studies  
 
After the scanning period, the anesthetized animals were sacrificed. Blood was collected, and 
plasma and a cell fraction were obtained from the blood sample by short centrifugation (5 
min at 1,000g). Several brain areas and peripheral tissues (Table 2) were excised. All tissue 
samples were weighed. The radioactivity in tissue samples was measured using a 
gamma-counter, applying a decay correction. The results were expressed as dimensionless 
SUVs. The parameter SUV is defined as tissue activity concentration (MBq/g) x [body 
weight (g)/injected dose (MBq)].  
 
 
2.2.6 Metabolite Analysis 
 
 A separate group of animals (n = 6) was used for metabolite analysis. In these rats, a 
small-animal PET scan was obtained and a biodistribution study was performed, but a 
smaller series of arterial blood samples was drawn (at intervals of 5, 10, 20, 40, and 60 min 
after tracer injection, volume increasing from 0.3 to 0.7 mL). Plasma was acquired by short 
centrifugation (Eppendorf centrifuge, 5 min at 13,000 rpm). Protein was removed by mixing 
plasma with an equivalent volume of 20% trichloroacetic acid in acetonitrile, followed again 
by short centrifugation. The protein free supernatant was injected into a high-performance 
liquid chromatography system (stationary phase, uBondapak, 7.8 x 300 mm [Waters]; mobile 
phase, 3% triethylamine and phosphate, pH 2.0: acetonitrile, 60:40 v/v, with a flow rate of 2 
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(and nonradioactive MPDX) was 
about 11 min. Two radioactive metabolites eluted at shorter retention times (6 and 8 min, 
respectively). This reversed-phase system is a slightly modified version of a published 
analytic procedure (24). One-milliliter samples of the eluate were collected at 0.5-min 
intervals. Radioactivity in these samples was determined. 
 
2.2.7 Statistical Tests 
 
Differences between groups were analyzed using 1-way ANOVA. A probability smaller than 




2.3.1 Small-Animal PET Images  
 
Small-animal PET images acquired after injection of [
11
C]-MPDX are presented in Figure 1. 
In saline-treated control animals, the brain was clearly visualized. High tracer uptake was 
observed in the hippocampus, cerebellum, and striatum (left panel) in addition to some areas 
of the cortex (image not shown). After pretreatment of rats with DPCPX, cerebral uptake of 
the tracer was strongly reduced, and regional differences in tracer uptake were no longer 
apparent (middle panel). When animals were pretreated with ethanol and the AKI ABT-702, 














Fig.1 MicroPET images of rat brain acquired after injection of [11C]-MPDX. Left: 
Untreated control animal, Middle: Animal pretreated with DPCPX, Right: animal   




2.3.2 Kinetics of Radioactivity in Brain and Plasma 
 
Cerebral kinetics of [
11
C]-MPDX –derived radioactivity (PET SUV in the whole brain as a 
function of time) are presented in Fig 2. In saline-treated control animals, uptake of the 
tracer rapidly increased to a maximum, which was already reached between 7 and 12 min, 
and was followed by washout. In animals pretreated with DPCPX, only a rapid washout of 
tracer was observed, and the cerebral uptake of 
11
C was strongly reduced. In rats pretreated 
 
with ABT-702 and ethanol, cerebral uptake of radioactivity was significantly increased, 
compared with the control group. Maximal tracer uptake now occurred after 13–20 min and 
was followed by washout. 
On the basis of SUVs measured with small-animal PET, A1R densities reported in the 
literature (e.g., 5,003 fmol of protein per milligram in rat hippocampus (25), injected masses 
of the tracer (Table 1), and assuming that cerebral tissue contains 10% protein, we estimate 
that less than 5% of the A1R population in the rat brain was occupied by [
11
C]-MPDX under 





are presented in Figure 2. A rapid, biexponential clearance was observed in all 
groups. Treatment of animals with DPCPX or a combination of ethanol and AKI (ABT-702) 
did not significantly affect tracer clearance from the plasma compartment. Areas under the 
curve (percentage of control) were 100.0 ± 8.4, 95.5 ± 6.6, and 96.0 ± 7.5 for the baseline, 














Fig.2. Kinetics of [
11
C]-MPDX
 –derived radioactivity in rat brain (left) and plasma (right). 
Error bars indicate SEM. Plasma data are not corrected for metabolites. ● = control group; 
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2.3.3 Metabolite Analysis 
 




was studied in 2 untreated control animals, 2 rats treated with ethanol and ABT-702, and 2 




was found to be hardly metabolized. 
The fraction of parent compound decreased from almost 100% at time zero to 82% – 84% 














Fig.3. Fraction of plasma radioactivity representing parent [
11
C]-MPDX. Pooled data are 
used because group differences were not observed. Error bars indicate SEM. 
 
 
2.3.4 Biodistribution  
 
Biodistribution data of 
11




 are presented 
in Table 2. Pre-treatment of animals with DPCPX resulted in a highly significant reduction 
of tracer uptake in all studied brain areas. Among peripheral organs, a significant reduction 
of tracer uptake was observed only in the spleen. DPCPX treatment caused a significant 
increase of the amount of radioactivity in the liver. Renal uptake of the tracer appeared to be 
increased as well, but the change was relatively small and this trend did not reach statistical 
significance. Treatment of rats with ethanol and ABT-702 increased uptake of radioactivity 
in the brain. This increase was statistically significant in the amygdala, cerebellum, 
entorhinal cortex, hippocampus, medulla, and pons. In other brain areas, an increase was also 
noted but this trend did not reach statistical significance because of a relatively large 
individual variance in the study groups. Outside the brain, increases of tracer uptake were 
noted in lungs, skeletal muscle, pancreas, and red blood cells after treatment of animals with 













































Amygdala 0.75 ± 0.09 0.27 ± 0.05 < 0.0001 1.12 ± 0.12 < 0.0005 
Bulbus olf 0.64 ± 0.18 0.34 ± 0.07 < 0.01 0.75 ± 0.27 NS 
Cerebellum 1.34 ± 0.29 0.46 ± 0.09 0.0001 2.16 ± 0.42 < 0.01 
Cingulate  0.88 ± 0.16 0.35 ± 0.08 0.0001 1.13 ± 0.23 0.06 
Entorhinal 0.89 ± 0.10 0.37 ± 0.04 < 0.0001 1.27 ± 0.25 < 0.01 
Frontal 0.89 ± 0.20 0.30 ± 0.08 0.0002 1.16 ± 0.26 NS 
Hippocam
pus 




0.75 ± 0.18 0.42 ± 0.11 0.01 1.51 ± 0.29 < 0.001 
Par/Temp/ 
Occ 
0.97 ± 0.20 0.34 ± 0.07 0.0001 1.40 ± 0.48 NS 
Pons 0.89 ± 0.21 0.44 ± 0.14 < 0.01 1.45 ± 0.30 < 0.01 
Striatum 1.01 ± 0.13 0.31 ± 0.07 < 0.0001 1.18 ± 0.31 NS 
Bone 0.24 ± 0.04 0.22 ± 0.09 NS 0.24 ± 0.09 NS 
Colon 0.83 ± 0.21 0.61 ± 0.19 NS 0.71 ± 0.06 NS 
Duodenum 1.12 ± 0.33 0.95 ± 0.57 NS 1.19 ± 0.17 NS 
Fat  1.95 ± 1.15 1.52 ± 0.19 NS 1.06 ± 0.24 NS 
Heart 0.69 ± 0.14 0.66 ± 0.08 NS 0.85 ± 0.17 NS 
Ileum 1.52 ± 0.52 1.19 ± 0.41 NS 1.38 ± 0.43 NS 
Kidney 1.09 ± 0.18 1.26 ± 0.07 0.08 1.50 ± 0.50 NS 
Liver 2.94 ± 0.40 4.43 ± 1.03 < 0.02 3.63 ± 0.68 NS 
Lung 0.70 ± 0.09 0.73 ± 0.07 NS 0.88 ± 0.07 < 0.01 
Muscle 0.40 ± 0.09 0.48 ± 0.07 NS 0.53 ± 0.07 < 0.05 
Pancreas 0.98 ± 0.18 1.01 ± 0.23 NS 1.48 ± 0.22 < 0.005 
Plasma 0.77 ± 0.06 0.73 ± 0.13 NS 0.71 ± 0.13 NS 
Red cells 0.34 ± 0.04 0.38 ± 0.09 NS 0.44 ± 0.07 < 0.02 
Spleen 0.95 ± 0.14 0.65 ± 0.06 < 0.005 1.06 ± 0.26 NS 
Trachea 0.73 ± 0.15 0.81 ± 0.31 NS 0.85 ± 0.23 NS 
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2.3.5 Graphical Analysis of PET Data 
 
VT of tracer was calculated using a Logan plot (Fig. 4), time–activity curves from an ROI 
drawn around the entire brain, and radioactivity counts from arterial blood samples. VT of 
tracer was significantly decreased (by 63%) after pretreatment of animals with DPCPX and 
significantly increased (by 39%) after pretreatment with ethanol and ABT-702 (Table 3). 
 
Table 3. Results from graphical analysis and compartment modeling of PET data (ROI 
drawn around entire brain) 
 
Parameter VT (Logan 
plot) 
K1/k2 (2TCM) BPND (k3/k4) 
(2TCM) 
VT (2TCM) 
Control rats 1.52 ± 0.18 0.62 ± 0.17 1.52 ± 0.10 1.56 ± 0.37 
DPCPX 
pretreated 
0.57 ± 0.05 
(p < 0.0001) 
0.58 ± 0.07 
(NS) 
0.00 
(p < 0.0001) 
0.58 ± 0.07 
(p < 0.0001) 
EtOH/ABT702 
pretreated 
2.12 ± 0.25 
(p < 0.005) 
0.68 ± 0.17 
(NS) 
2.34 ± 0.64 
(p < 0.05) 
2.21 ± 0.44 
(p < 0.05) 
 
Mean ± S.D. P-values relate to the effect of pretreatment compared to untreated controls. 
 
 
2.3.6 Compartment Modeling of PET Data 
 
A 2TCM was fitted to time–activity curves from an ROI drawn around the entire brain, 
using radioactivity counts from arterial blood samples as an input function. A 
1-tissuecompartment model could not be fitted to the time–activity curves of control and 
ethanol and ABT-702 –treated animals at all, in contrast to a 2TCM. Thus, the 2TCM was 




(ratio K1/k2 from the model fit) 
was not significantly affected by any of the treatments, in contrast to BPND (Table 3). BPND 
was reduced to zero after treatment of animals with DPCPX and significantly increased (by 
54%) after treatment with ethanol and ABT-702. VT calculated from the 2TCM fit 
corresponded closely to VT acquired by graphical (Logan) analysis of the PET data, 
although the intraindividual variability was greater.VT (from the model fit) was significantly 
reduced (by 63%) after pretreatment of animals with DPCPX and significantly increased 












Fig,4. Logan plots (A) of control, ethanol and ABT-702–treated, and DPCPX-treated rats 
and 2TCM fit (B) for animal pretreated with ethanol and ABT-702. (A) ● = 5 control group; 
O = ethanol and ABT- 702–treated animals; ∆ =animals pretreated with DPCPX. (B)  = 
measured activity in brain; ⁭ = fitted activity in brain, ◊ = specific binding in brain; =  





2.4.1 Specificity of [11C]-MPDX Binding 
 
The regional distribution of radioactivity in the rat brain after injection of [
11
C]-MPDX (Fig. 
1, left) suggests that this tracer is capable of visualizing regional A1R densities. Further 




 was obtained by pretreating animals 
with the subtype-selective antagonist DPCPX. In pretreated animals, the brain uptake of 
radioactivity after injection of [
11
C]-MPDX was strongly suppressed, and regional 
differences were no longer evident (Fig. 1, middle; Fig. 2, top). A biodistribution study, 
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performed at 80 min after tracer injection, confirmed that uptake of radioactivity was 
reduced by DPCPX to a low value that was homogeneous throughout the brain (Table 2). 
The greatest declines were observed in the hippocampus (72%), striatum (69%), cerebellum 
(66%), frontal cortex (66%), parietal cortex (65%), and amygdala (64%). Outside the brain, 
a reduction of [
11
C]-MPDX uptake was observed only in the spleen, possibly reflecting 
specific binding of the tracer to A1R, because A1Rs are involved in splenic contraction 
(26).DPCPX caused a significant increase of the levels of radioactivity in rat liver and 
tended to increase renal activity levels as well (Table 2), indicating that after blocking of 
the receptor compartment, a greater fraction of the injected dose is taken up by organs 







































in rat brain and regional 
adenosine A1 receptor density as known from autoradiography 
 




in various brain areas (uptake in saline-treated control animals minus uptake in animals 
pretreated with DPCPX, Table 2) against regional A1R numbers, known from 
autoradiography (27–29). The regions plotted were the amygdala, cerebellum, cingulate, 
entorhinal, and frontal cortices; hippocampus; medulla; parietal–temporal–occipital cortex; 
pons; and striatum. Receptor density in the hippocampus (main target region) was set to 
100%, to allow the use of data from several published studies. An excellent correlation was 
observed between literature values for A1R density and [
11
C]-MPDX  uptake at 80 min 
after injection (Fig. 5).Data analysis of the cerebral time–activity curves in saline- and 




 to cerebral A1R. 
Tracer VT in the entire brain—calculated either by graphical analysis or by kinetic modeling 
of the PET data—showed a decline (>60%) similar to that of tracer SUV measured after 80 




estimated by fitting a 2TCM was reduced 





is absent in DPCPX-treated animals. 
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2.4.2 Effect of Ethanol and Inhibition of Adenosine Kinase 
 
Acute administration of ethanol is known to result in strong increases of extracellular 
adenosine both in cell culture and in the rat brain in vivo, which can be assessed by 
microdialysis (17). Two different mechanisms may underlie this effect of ethanol. First, 
ethanol is metabolized to acetate and acetyl-coA before entering the tricarboxylic acid 
cycle. Increased flux through acetyl coA-synthetase leads to increased production of 
adenosine from adenosine monophosphate via 5’-nucleotidase and stimulation of cellular 
adenosine release (18). Second, ethanol blocks nucleoside transporters in cellular 
membranes, particularly the type 1 equilibrative nucleoside transporter (19,20,30,31). 
Increased binding of adenosine to cerebral A1R is believed to be an important factor 
underlying the motor incoordination (32–35) and sleep-promoting (36) effects of ethanol  
The coadministration of an AKI (e.g., ABT-702) with ethanol leads to even stronger 
increases of extracellular adenosine, because phosphorylation of adenosine by the enzyme 
AK is normally the primary route of adenosine metabolism. Inhibition of AK decreases the 
rate of adenosine inactivation and locally enhances extracellular adenosine 
concentrations—not at baseline but rather under conditions of increased formation of 
adenosine. Orally administered AKIs are known to raise regional concentrations of 
endogenous adenosine in the brain (15, 16), and for this reason, these compounds have 
therapeutic potential as analgesic, antiinflammatory, and antiepileptic agents (14, 37). 
Because both ethanol administration and AK inhibition are known to increase the levels of 





in the rat brain after acute treatment of rats with ethanol and ABT-702. 





for cerebral A1R are in the same (nanomolar) range (38). 
However, in ethanol and ABT-702–pretreated animals, we observed a paradoxic increase 
rather than a decrease of cerebral tracer binding. Statistically significant increases occurred 
in PET SUV (Figs. 1 and 2), SUV from an ex vivo biodistribution study (Table 2), and tracer 
VT (Table 3). 
Kinetic modeling was performed to gain more insight into the mechanisms underlying 
the paradoxic increase of cerebral radioactivity induced by ethanol and ABT-702. Fitting of a 
2TCM to the cerebral time–activity curves of control and treated animals indicated that the 
partition coefficient of the tracer (K1/k2) was not affected by treatment, in contrast to BPND, 
which showed a significant increase (Table 3). The fit data, and also our data on tracer 
clearance (Fig. 2) and metabolism (Fig. 3), suggest that tracer delivery is not changed by 
treatment. Increases of the apparent A1R densities (on average, 35%; maximally, 55%) in the 
brain of rats and mice have been reported, both after acute (32,39) and after chronic (39,40) 
administration of ethanol, using ex vivo binding assays. Such changes could cause increased 
cerebral binding of [
11
C]-MPDX after treatment of rodents with ethanol and ABT-702. 
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However, further studies are necessary to identify the mechanism underlying increased 









and small-animal PET. In the brain of untreated control animals, the highest 
levels of tracer uptake were observed in target regions with a high density of A1R, such as the 
hippocampus, striatum, cerebellum, and cerebral cortex (Fig. 1). Pretreatment of animals 
with the specific A1R antagonist DPCPX resulted in a strong suppression of tracer uptake in 
the central nervous system and an abolishment of the regional differences (Fig.1; Table 2). 
Specific binding of the tracer in various brain regions corresponded closely to regional A1R 
densities known from autoradiography (Fig. 5). Tracer binding can be quantified both by 
graphical analysis (Logan plot, calculation of VT) and by kinetic modeling (BPND or VT  from 
2TCM (Table 3). The PET data did not provide evidence for increased competition of 
endogenous adenosine after acute treatment of animals with ethanol and ABT-702, but a 




 was noted in the rat brain (Figs. 1 and 2; Tables 
2 and 3), which may correspond to increases of apparent A1R density reported in the 
literature. Further studies are necessary to elucidate the mechanisms underlying the enhanced 
[
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Chapter III 
 
[11C]-MPDX and PET to study adenosine A1 
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and PET. Here we investigated whether A1R occupancy by 
non-radioactive agonists and antagonists can be assessed with this technique. Methods: 
MicroPET scans with arterial blood sampling were made in four groups of 
isoflurane-anesthetized Wistar rats: (1) Controls (n = 7) (2) Pretreated with a centrally active 
A1R agonist, N
6
-cyclopentyladenosine (CPA, 0.25 mg/kg i.p., Kd 0.48 nM, n = 7) (3) 
Pretreated with a moderate dose of caffeine (antagonist for A1 and A2A receptors, 4 mg/kg i.p., 
Kd 11 µM, n = 6) and (4) pretreated with a high dose of caffeine (40 mg/kg i.p., n = 6). Results: 
Administration of CPA resulted in a strong reduction (>50%) of heart rate, and caffeine 
administration in a small increase (10-15%). A caffeine dose of 4 mg/kg (n=6) resulted in 
65.9% A1R occupancy and a 40 mg/kg dose (n=4) in 98.5% occupancy (calculated from 








can be used to assess antagonist 
but not agonist binding at A1Rs. Changes of tracer uptake after administration of CPA resemble 
previously reported changes induced by treatment of rats with ethanol and an adenosine kinase 
inhibitor (ABT702). Thus, administration of an exogenous agonist or raising the levels of the 
endogenous agonist have similar effects. Agonists and antagonists may bind to different sites 
on the A1R protein having allosteric interactions.   
 
Keywords: adenosine A1 receptor, occupancy, N
6
-cyclopentyladenosine, caffeine, brain 
3.1 Introduction 
Adenosine A1 receptors (A1Rs) are G-protein-coupled binding sites for the 
endogenous neuromodulator adenosine which inhibit formation of the second messenger, 
cyclic AMP. They are implicated in the regulation of neuronal activity, neuroprotection and 
neuroinflammation (1). Some A1R agonists may be beneficial in the treatment of atrial 
arrhythmias, type 2 diabetes and angina (2). 
    Cerebral A1Rs can be visualized using positron emission tomography (PET) and 
















 can be used to 
quantify regional A1R densities in rodent brain with microPET (7). PET offers the unique 
opportunity of measuring the fraction of receptor populations occupied by non-radioactive 
drugs in the living brain and relating levels of occupancy to the magnitude of the 
therapeutic effect or to unwanted side effects. Receptor occupancy is estimated by assessing 
competition of a non-radioactive drug with the radioligand for the same binding sites.  
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In order to explore the interaction of therapeutic drugs with A1R, we have treated 




-microPET scan: (i) 
N
6
-cyclopentyladenosine (CPA) and (ii) caffeine. CPA is a potent adenosine receptor 
agonist (Kd 0.48 nM) with considerable selectivity for the A1 subtype (8,9). Caffeine is a 
non-subtype-selective adenosine antagonist with moderate affinity (IC50 values 11 to 85 
µM), which is widely consumed as a recreational drug (10,11). Occupancy of cerebral A1Rs 
by caffeine or the potent (Kd 0.42 nM) and highly subtype-selective A1R antagonist DPCPX 
(12,13) has been visualized using the tracers [
18




 (7) and 
PET. However, PET studies of the occupancy of cerebral A1R by agonists have never been 
reported. Our present findings together with previous studies indicate that dose-dependent 
occupancy of the A1R population by antagonists can be assessed with PET. However, 
administration of a high dose of the agonist CPA which strongly decreases heart rate, body 
temperature and locomotor activity in rodents (16) does not result in any measurable 




 in rodent brain. 
 
3.2 Materials and Methods 
 
3.2.1 (Radio) chemicals 
 





 was prepared as described previously (7). 
 
3.2.2 Experimental Animals 
All animal experiments were performed by licensed investigators in compliance with the 
Law on Animal Experiments of The Netherlands. The protocol was approved by the 
Committee on Animal Ethics of Groningen University. Male outbred Wistar-Unilever (SPF) 
rats (body weight 304 ± 54 g) were obtained from Charles-River, maintained at a 12-h 
light/12-h dark regime and fed standard laboratory chow ad libitum. Four groups of animals 
were studied: 1) Controls (pretreated with saline, i.p., n = 7); 2) Animals pretreated with 
CPA (0.25 mg/kg, i.p., dissolved in 0.3 mL saline containing < 50 µL dimethyl sulfoxide,  
n = 7, see (16) 3) Animals pretreated with a moderate dose of caffeine (4 mg/kg, i.p., 
dissolved in saline, n = 6); and 4) Animals pretreated with a high dose of caffeine (40 
mg/kg, i.p., dissolved in saline, n = 6). All treatments were given 5 to 10 min before 
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Table 1. Animal Data 
 




Control (n=7) 311 ± 56 23.3 ± 4.0 2.1 ± 0.4 
CPA (n=7) 312 ± 31 25.7 ± 5.5 2.4 ± 0.5 
Caffeine 4 mg/kg 
(n=6) 
317 ± 90 23.4 ± 7.9 2.1 ± 0.7 
Caffeine 40 mg/kg  
(n=6) 
275 ± 19 12.1 ± 13.8 1.1 ± 1.3 
 
3.2.3 PET Scanning 
 Two rats were scanned simultaneously, using a Focus 220 microPET camera 
(Siemens-Concorde, Knoxville, TN). Animals were anesthetized with a mixture of 
isoflurane/air (ratio 5% during induction, later reduced to ≤ 2%). Cannulas were placed in a 
femoral artery and vein for blood sampling and tracer injection, respectively. A 
transmission scan was made, using an external source of radioactive cobalt, in order to 




emission images for attenuation and scatter. 
Rats were under anesthesia for 30–40 min before tracer injection (time required for 
cannulation and transmission scan). The tracer ([
11
C]-MPDX, 21.5 ± 9.7 MBq in volume of 
1 mL) was injected through the venous cannula, as a slow (1 min) bolus, using a 
Harvard-style pump. The camera was started as soon as the tracer entered the body of the 
first rat in the scanner; the second animal of the pair was injected 16 min later. Scanning 
was then continued for another 60 min. The animal that was injected last was also 
anesthetized at a later moment. Thus, the duration of anesthesia was similar in all study 
groups. A list-mode protocol was used (76 min, brain in the field of view). A series of blood 
samples (18 samples; volume, 0.10–0.15 mL) was drawn, initially in rapid succession (5 s) 
and later at longer intervals (up to 30 min). Plasma was acquired from these samples by 
centrifugation (Eppendorf centrifuge, 5 min at 13,000 rpm). Radioactivity in 25 µL of 
plasma and 25 µL of whole blood was counted and used as an arterial input function. 
During the entire scanning procedure, heart rate, stroke volume and blood oxygen level of 
the animals were monitored, using pulse oximeters (Nonin Pulse Sense). 
 
3.2.4 Analysis of PET Data 
List-mode data were reframed into a dynamic sequence of 8 × 30, 3 × 60, 2 ×120, 2 
× 180, 3 × 300, 1 × 480, 3 × 600, and 1 × 960 s frames. The data were reconstructed per 
time frame using an iterative reconstruction algorithm (attenuation-weighted 2-dimensional 
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ordered-subset expectation maximization, provided by Siemens; 4 iterations, 16 subsets; 
zoom factor 2). The ﬁnal datasets consisted of 95 slices, with a slice thickness of 0.8 mm 
and an in-plane image matrix of 128 ×128 pixels of size 1.1 mm. Datasets were fully 
corrected for random coincidences, scatter, and attenuation. Images were smoothed with a 
Gaussian ﬁlter (1.35 mm in both directions). 
Time–activity curves (TACs) and volumes (cm3) for the regions of interest (ROIs) 
were calculated using the Siemens Inveon Research Work Place 4.0 (IRW 4.0). ROIs were 
drawn around the (entire) bulbi olfactorii, frontal cortex, striatum, amygdala, 
parietal/temporal/occipital cortices, medulla, cerebellum, pons and hippocampus in a 
template MRI scan that was co-registered with the PET scan of interest by image fusion 
(17). Standardized uptake values measured by PET (PET-SUVs) were calculated, using 
measured body weights and injected doses [tissue activity concentration 
(MBq/mL)]/[(injected dose (MBq)/body weight (g)]. The cerebral distribution volume (VT) 
of the tracer was estimated either from a Logan plot (linear regression started 10 min after 
tracer injection) or a 2-tissue-compartment model (2TCM) fit. For Logan graphical 
analysis, blood volume was fixed to 3.6% (18). The partition coefficient (K1/k2) and 




were estimated from the model fit. 
Since there is no region with negligible A1R expression in the rodent brain, levels of 
receptor occupancy were calculated by comparing regional VT levels in control and 
drug-treated rats, using a modified (i.e., axes-transformed) Lassen plot (19).  
 
3.2.5 Biodistribution Studies 
After the PET scan, the anesthetized animals were sacrificed. Blood was collected, and 
plasma was obtained from the blood sample by centrifugation (5 min at 1,000 × g). Several 
areas of the brain were dissected and peripheral organs were excised. These tissue samples 
were weighed and tissue radioactivity was measured with a gamma counter, applying a 
decay correction. Tracer uptake was expressed as a dimensionless SUV.  
 
3.2.6 Statistical Tests 
Differences between groups were analyzed using 1-way ANOVA. A probability smaller 
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3.3 Results 
3.3.1 Physiological Responses to Drug Treatment 
About 5 min after administration of the A1R agonist CPA, a very strong decline of heart rate 
was noted (> 50%). This decline persisted for the entire duration of the microPET scan (60 
min), although a slight return to baseline occurred near the end of the scan. The decline of 
heart rate was accompanied by an increase of cardiac stroke volume. Blood oxygenation 
levels were not significantly altered. Administration of caffeine resulted in small (10 to 
15%) increases of heart rate after 5 min which persisted for the entire duration of the scan, 
and no significant change of blood oxygenation. 
 
3.3.2 Animal PET Images 
The PET images that were acquired in this study were very similar to those reported 
previously (7). When animals were pretreated with the A1R agonist CPA, a global increase 
of tracer uptake was noted, compared with the control group. After pretreatment of rats with 
caffeine (particularly at the highest dose), cerebral uptake of the tracer was strongly reduced 
and regional differences in tracer uptake were no longer apparent. 
 
3.3.3 Kinetics of Radioactivity in Brain and Plasma 
Cerebral kinetics of radioactivity were also very similar to those reported previously (7). In 
rats pretreated with CPA, uptake of radioactivity was increased compared to the control 
group (Fig. 1). In animals pretreated with caffeine, a rapid washout of tracer was observed, 
and the brain uptake of 
11
C was strongly reduced (Fig.1).  
 
Clearance of radioactivity from plasma appeared to be little affected by drug treatment. 
Although the shape of the plasma curve was different after treatment of animals with CPA, 
a stronger initial rise of plasma radioactivity being followed by a greater decline (Fig. 2), 
areas under the curve were similar in the four treatment groups. Expressed as a percentage 
of control, they were 92 ± 9 % (CPA), 112 ± 20% (caffeine 4 mg/kg), 104 ± 19% (caffeine 
40 mg/kg) and 100 ± 16% (saline-treated control), respectively. None of these differences 
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-derived radioactivity in rat brain. Error bars indicate 
SEM. Closed dots = control animals, open dots = CPA-treated, open squares = caffeine 4 













-derived radioactivity in rat plasma. Error bars 
indicate SEM. Closed dots = control animals. Open dots panel A = CPA-treated, open dots 
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3.3.4 Biodistribution Data 
The biodistribution data which were acquired after the PET scan (Table 2) corresponded 
closely to PET-SUV data in the last scan frame. Treatment of rats with CPA did not result in 
any decrease but rather an increase of cerebral radioactivity. This increase was statistically 
significant in the amygdala, cerebellum, frontal cortices, hippocampus, medulla, parietal, 
temporal and occipital cortex, striatum and rest of the brain. In entorhinal cortex and pons, 
an increase was also noted but this trend did not reach statistical significance because of a 
relatively large individual variance in the study groups. Outside the brain, tracer uptake was 
increased only in the liver (Table 2). 
Pretreatment of animals with caffeine (4 mg/kg) reduced tracer uptake in cingulate, 
entorhinal, and frontal cortices, hippocampus, medulla and striatum. Among peripheral 
organs, a significant reduction of tracer uptake was observed only in the spleen. Levels of 
radioactivity in urine were increased (Table 2)  
Pretreatment of rats with a high dose of caffeine (40 mg/kg) resulted in a highly significant 
reduction of tracer uptake in virtually all studied brain areas, with exception of pons and 
medulla (Table 2). Outside the brain, significant reductions of tracer uptake were noticed in 
spleen and duodenum, whereas uptake in the trachea was increased (Table 2). 
 
3.3.5 Graphical Analysis of PET Data 
Tracer VT was calculated using a Logan plot, time–activity curves from an ROI drawn 
around the entire brain, and radioactivity counts from arterial blood samples. Compared to 
saline-treated controls, there was a significant increase in VT after pretreatment of animals 
with CPA (from 1.60 ± 0.23 to 2.38 ± 0.36, p = 0.0005) and a significant decrease after 
treatment with caffeine (from 1.60 ± 0.23 to 0.86 ± 0.08, p < 0.0001, after the 4 mg/kg 
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Table 2. Biodistribution data of [11C]-MPDX, 80 min after injection 
 
Tissue Control  
(n = 7) 
Treated with 
CPA (n = 7) 
Caffeine 4 
mg/kg (n = 6) 
Caffeine 40 
mg/kg (n = 6) 
Amygdala 0.92 ± 0.23 1.29 ± 0.11* 0.69 ± 0.18 0.52 ± 0.08* 
Olfactory bulb 0.70 ± 0.24 0.78 ± 0.21 0.58 ± 0.28 0.43 ± 0.13* 
Cerebellum 1.41 ± 0.24 2.23 ± 0.50* 1.10 ± 0.32 0.69 ± 0.15* 
Cingulate 1.11 ± 0.27 1.05 ± 0.22 0.60 ± 0.16* 0.57 ± 0.18* 
Entorhinal 1.23 ± 0.33 1.40 ± 0.20 0.66 ± 0.18* 0.59 ± 0.16* 
Frontal 1.04 ± 0.26 1.30 ± 0.16* 0.67 ± 0.17* 0.51 ± 0.09* 
Hippocampus 1.18 ± 0.25 1.55 ± 0.15* 0.82 ± 0.30* 0.57 ± 0.12* 
Medulla 0.90 ± 0.16 1.23 ± 0.28* 0.70 ± 0.17* 0.71 ± 0.20 
Parietal, temporal 
and occipital cortex 
 
1.19 ± 0.30 
 
1.62 ± 0.39* 
 
0.88 ± 0.24 
 
0.55 ± 0.08* 
Pons 0.89 ± 0.27 1.12 ± 0.30 0.72 ± 0.18 0.64 ± 0.24 
Striatum 1.13 ± 0.19 1.40 ± 0.20* 0.81 ± 0.23* 0.50 ± 0.07* 
Rest of the brain 1.17 ± 0.27 1.53 ± 0.34* 0.89 ± 0.28 0.59 ± 0.10* 
Bone 0.29 ± 0.14 0.33 ± 0.11 0.32 ± 0.06 0.35 ± 0.05 
Colon 0.80 ± 0.30 0.98 ± 0.44 0.90 ± 0.19 1.01 ± 0.22 
Duodenum 1.50 ± 0.29 1.63 ± 0.65 1.74 ± 0.56 1.02 ± 0.28* 
Fat 1.78 ±0.43 1.41 ± 0.30 2.37 ± 1.23 1.99 ± 1.02 
Heart 0.80 ± 0.14 0.99 ± 0.18 0.91 ± 0.21 0.86 ± 0.15 
Ileum 1.24 ± 0.29 1.26 ± 0.38 1.31 ± 0.45 1.12 ± 0.17 
Kidney 1.31 ± 0.15 1.49 ± 0.24 1.19 ± 0.25 1.45 ± 0.21 
Liver 2.69 ± 0.49 3.25 ± 0.33* 3.09 ± 0.67 2.74 ± 0.48 
Lung 0.86 ± 0.10 0.87 ± 0.09 0.85 ± 0.14 0.95 ± 0.19 
Muscle 0.45 ± 0.06 0.53 ± 0.11 0.54 ± 0.09 0.50 ± 0.12 
Pancreas 1.24 ± 0.27 1.37 ± 0.25 1.37 ± 0.48 1.51 ± 0.46 
Plasma 0.90 ± 0.11 0.78 ± 0.10 0.92 ± 0.16 0.87 ± 0.17 
Red Cells 0.42 ± 0.06 0.46 ± 0.08 0.41 ± 0.12 0.47 ± 0.09 
Spleen 1.22 ± 0.18 1.15 ± 0.20 0.97 ± 0.20* 0.81 ± 0.18* 
Trachea 0.64 ± 0.18 0.66 ± 0.13 0.84 ± 0.20 1.15 ± 0.20* 
Urine 0.32 ± 0.39 0.03 ± 0.02 1.14 ± 0.73* 0.40 ± 0.88 
SUV values are listed as mean ± SD. Significant differences between treatment and 










                                 
 
 




in whole brain calculated from a Logan plot 



















Figure 4. Partition coefficient (K1/k2) and binding potential (k3/k4) of [
11
C]-MPDX in 
whole brain calculated from a 2-tissue compartment model fit. 
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3.3.6 Compartment Modeling of PET Data 
 
When a 2TCM was fitted to time–activity curves from a ROI drawn around the entire brain, 
using radioactivity counts from arterial blood samples as input function, the partition 
coefficient of [
11
C]-MPDX  (ratio K1/k2 from the model fit) was found to be not 
significantly affected by CPA, but significantly decreased after treatment of animals with 
caffeine (Fig.4). Receptor occupancy by caffeine (calculated by the formula 
100*(1-BPdrug-treated/BPcontrol) was 69.8% for the 4 mg/kg dose and 100% for the 40 mg/kg 
dose. Tracer k3/k4 was significantly increased after treatment with CPA and significantly 
decreased by caffeine (Fig. 4). The PET data for the high-dose caffeine group were better 
fitted by a 1-tissue compartment model (1TCM) than a 2TCM, in contrast to the data from 
the three other treatment groups. Blood volume could be left floating during the 2TCM or 
1TCM fits. The value estimated by the fit program was 3.3 ± 0.4% (mean ± s.e.m., n = 21). 
However, in some animals the program estimated a blood volume of zero percent. Data of 








Figure 5. Lassen plots for A1R occupancy by caffeine (open squares = 4 mg/kg, closed 
squares = 40 mg/kg). VT: distribution volume. 
 
3.3.7 Estimation of Receptor Occupancy 
Modified Lassen plots were prepared using the regional Logan VT values of animals in the 
control, low dose caffeine and high dose caffeine groups (Fig. 5). Both plots showed good 
correlation coefficients with r
2
 values of 0.9738 and 0.9086, respectively. Receptor 
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occupancy by caffeine (estimated from the slope of the plot) was 65.9% for the 4 mg/kg 
dose and 98.5% for the 40 mg/kg dose. VT of the nonspecific binding (estimated from the 
X-intercept of the plot) was about 0.5, i.e. less than 25% of total VT in the target regions 
with the highest A1R expression, hippocampus and cerebellum.  
 
3.4 Discussion 
The drug doses which we administered were based on data reported in the literature. CPA, 
at a dose of 0.25 mg/kg, causes a strong hypothermic response in the rat which persists for 
at least 2 h. After repeated administration on subsequent days, a downregulation of cerebral 
A1R is observed which is particularly significant in the hippocampus and somatosensory 
cortex, and the A1R system is functionally desensitized (16). Thus, CPA enters the brain and 
interacts with cerebral A1R. Caffeine, at a dose of 4 mg/kg, has been shown to compete 
with the ligand 
18
F-FPCPX for binding to adenosine A1R in rat brain (14). Although the 
agonist mass which we injected was an order of magnitude smaller than the mass of the 
antagonist (0.25 and 4 mg/kg, respectively), in functional terms the agonist dose was much 
greater, since the affinity of CPA for A1R is in the sub-nM range (8,9) whereas the affinity 
of caffeine for A1R and A2AR is in the 10
-5
 M range (10,11). Yet, competition between 




for binding to cerebral A1R was observed, but 
competition between non-radioactive CPA and the radioligand was undetectable.  
    Values of A1R occupancy by caffeine could be calculated from a modified Lassen plot 
((19), Fig.5). A similar plot made from previously published data (7) indicated that 
administration of 3.2 mg/kg of the selective A1R antagonist DPCPX was associated with 





, although the CPA dose which we injected caused a very strong decline of 
heart rate and was close to the upper limit which could be tolerated by our animals. This 
observation may indicate that purine agonists and xanthine antagonists interact differently 
with the A1R pharmacophore. Experiments in which A1R were chemically modified or 
altered by site-directed mutagenesis have indeed shown that agonists and antagonists bind 
to different domains of the A1R protein (20,21). 




binding in the rodent brain after 
administration of CPA (Figs. 1, 3 and 4; Table 2). Compartmental analysis of brain TACs 
using data from arterial plasma samples as input function indicated that K1/k2 values were 
unchanged but binding potential (k3/k4) values were elevated after treatment of animals 




 data of 
animals which had been treated with ethanol and the adenosine kinase inhibitor ABT702, in 
order to raise the endogenous levels of extracellular adenosine (7). These kinetic modeling 




across the blood-brain 
barrier are not altered in the presence of CPA (or ethanol and ABT702), but the availability 
of A1R or the affinity of A1R for the radioligand is increased. 
                                                                       93 




 in the 
presence of CPA or increased levels of extracellular adenosine is the hypothesis that 
agonists and antagonists bind to different domains on a single A1R protein or to different 
protomers in a A1R homodimer (22), agonist binding causing a conformational change of 
the receptor protein (or receptor complex) which facilitates the subsequent binding of an 
antagonist. Data from a few reports involving isolated biomembranes or brain slices have 
suggested that A1R agonists can indeed increase the binding of A1R antagonists to A1R  
(23,24), and vice versa (22). 
3.5 Conclusion 





for binding to A1R in the brain of living rodents was observed with microPET 
and values for dose-dependent receptor occupancy could be calculated from a modified 
Lassen plot (Fig. 5). However, administration of a high dose of an agonist with purine 




for binding to 
the target receptor. These data and the data from our previously reported microPET study 
with ethanol and ABT702 (7) suggest that adenosine analogs and xanthines bind to different 
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Chapter IV 
Cerebral adenosine A1 receptors are upregulated 
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Abstract 
 
Adenosine A1 receptors (A1Rs) are implied in the modulation of 
neuroinflammation.Activation of cerebral A1Rs acts as a brake on the microglial response 
after traumatic brain injury and has neuroprotective properties in animal models of 
Parkinson's disease and multiple sclerosis. Neuroinflammatory processes in turn may affect 
the expression of A1Rs, but the available data is limited and inconsistent. Here, we applied an 
animal model of encephalitis to assess how neuroinflammation affects the expression of 
A1Rs. Two groups of animals were studied: Infected rats (n = 7) were intranasally inoculated 
with herpes simplex virus-1 (HSV-1, 1 x 10
7
 plaque forming units), sham-infected rats (n = 
6) received only phosphate-buffered saline. Six or seven days later, microPET scans (60 min 





C]-MPDX). Tracer clearance from plasma and partition coefficient 
(K1/k2 estimated from a 2-tissue compartment model fit) were not significantly altered after 
virus infection. PET tracer distribution volume calculated from a Logan plot was 
significantly increased in the hippocampus (+37%) and medulla (+27%) of virus infected 
rats. Tracer binding potential estimated from the model fit was significantly increased in 
cerebellum (+87%) and medulla (+148%) which may indicate increased A1R expression. 
This was confirmed by immunohistochemical analysis showing a strong increase of A1R 
immunoreactivity in cerebellum of HSV-1-infected rats. Both the quantitative PET data and 
immunohistochemical analysis indicate that A1Rs are upregulated in brain areas where active 
virus is present. 








Neuroinflammation is an important aspect of the pathophysiology of neurodegenerative 
diseases. The nucleoside adenosine may have neuroprotective properties by reducing 
neuronal excitability [26] and acting as an anti-inflammatory agent [10]. Such effects 
appear to be mediated by adenosine A1 receptors (A1Rs) in the central nervous system. 
A1Rs are expressed both on neurons and on glia [16]. Activation of cerebral A1Rs acts as a 
brake on the microglial response after traumatic brain injury [17] and has neuroprotective 
effects in animal models of Parkinson’s disease [20] and multiple sclerosis (MS) [9.32]. 
Neuroinflammation after chronic infusion of lipopolysaccharide (LPS) into the fourth 
ventricle of young rats, and natural microglia activation in aged rats are both attenuated 
after treatment of animals with caffeine [6]. 
Upregulation of A1Rs in the human brain may also have neuroprotective properties 
and suppress neuroinflammation. A recent paper reported that a higher cerebrospinal fluid 
caffeine concentration is associated with a more favorable outcome after severe traumatic 
brain injury [28]. Moreover, regular caffeine consumption is associated with lower risk for 
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developing Parkinson’s disease [25] or Alzheimer dementia [8]. Changes of A1R signaling 
have been reported in patients with MS. Plasma levels of adenosine in such patients are 
significantly reduced. Stimulation of peripheral blood mononuclear cells (PBMC) with a 
selective A1R agonist R-PIA inhibits the mitogen-stimulated production of the 
inflammatory marker TNF-alpha in healthy volunteers but not in subjects with MS [22]. 
Taken together, the above-mentioned results indicate that A1R upregulation and 
stimulation may affect neurodegenerative and neuroinflammatory processes. In addition, 
some studies have suggested that neuroinflammation itself may also affect the expression of 
A1Rs. For example, A1R densities in PBMC and in brain tissue from MS-patients are 
significantly decreased (by 53% and 49%, respectively) compared to age-matched controls 
[19]. In agreement with this is the finding of reduced densities of A1Rs in microglia of 
wild-type mice during experimental autoimmune encephalomyelitis [32]. However, acute 
inflammation of mouse brain after administration of LPS was shown to increase A1R 
expression in cortical areas and this response was dependent on the transcription factor 
NF-kappaB [18]. If combined, these data suggest that A1Rs are up-regulated in acute forms 
of neuroinflammation but down-regulated in chronic forms. Clearly, more data is required. 





C-MPDX) in a rodent model of 
encephalitis (nasal infection of Wistar rats with HSV-1). 
11
C-MPDX has been used 
previously for PET studies of A1Rs, both in animals [24, 29, Chapters 2 and 3] and humans 
[13-15]. The present study aimed to assess whether binding of 
11
C-MPDX and 
immunoreactivity of the A1R protein are altered in rat brain as a consequence of 
neuroinflammation. 
     
4.2 Materials and methods 
 
4.2.1 Animals and housing 
 
The animal experiments were performed by licensed investigators in compliance with the 
Law on Animal Experiments of The Netherlands. The protocol was approved by the 
Committee on Animal Ethics of the University of Groningen. Male outbred Wistar-Unilever 
rats were obtained from Charles-River. The rats were housed in Macrolon cages (38 × 26 × 
24 cm) maintained at a 12-h light/12-h dark regime and were fed standard laboratory chow ad 
libitum. Two groups of animals were studied: rats infected with HSV-1 (n = 7) and 
sham-infected rats (n = 6). 
 
4.2.2 HSV-1 inoculation 
 
The HSV-1 strain was obtained from a human clinical isolate cultured in Vero-cells and 
assayed for plaque forming units (PFU) per mL. In order to infect rats with HSV-1, the 
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animals were anesthetized with 5% isoflurane. Subsequently, 1x10
7
 PFU HSV-1 in 100 uL 
phosphate-buffered saline (PBS) was applied in the nose using a micropipette (50 uL in each 
nostril). Sham-infected rats received 100 uL PBS without any virus. Clinical symptoms in all 
rats were observed daily and were recorded by scoring them in an animal welfare diary. 
Scores ranged from 0 to 3, with 0 indicating no particular response or symptoms; 1 
meaning ruffled fur, dried oral and nasal secretions on the fur, loss of weight; 2 indicating 
animals showed a hunched posture, increased aggression and paralysis symptoms in the 
posterior part of the abdomen; and score 3 indicating seizures, severe paralysis, difficulty of 
breathing, or death. In our study, score 3 was not reached as the ethics committee did not 
allow a longer interval than 8 days between virus inoculation and PET imaging. On day 6 or 
7, the rats were transported to the imaging facility for microPET scanning. 
 






was prepared by reaction of 
11
C-methyl iodide with the 
appropriate 1-N-desmethyl precursor. Briefly, 
11
C-methyl iodide was trapped in 0.3 mL of N, 
N-dimethylformamide containing 1 mg of 1-N-desmethyl precursor and 5 uL of NaOH and 
was heated at 120°C for 5 min. After 1.0 mL of 0.1 M HCl had been added, the solution was 
loaded onto a high-performance liquid chromatography column (Econosphere, C18, 5 mm 
[Altech]; 10 x 250 mm) and eluted with a mixture of 0.1 M NaH2PO4 and ethanol (70/30) at 
a flow rate of 4 mL/min. The fractions containing [
11





was 14 min. The decay-corrected radiochemical yield was 35% ± 5% 
(based on 
11
Cmethyl iodide), and the radiochemical purity was greater than 98%. MicroPET 
(Focus 220 camera, Siemens-Concorde) scans were made on day 6 or 7 after the inoculation 
with HSV-1. Two rats were scanned simultaneously in each data acquisition protocol. 
Approximately 30-40 min before tracer injection, animals were anesthetized with a mixture 
of isoflurane/air (inhalation anesthesia, 5% ratio during induction, later reduced to 2%). 
During this time, surgery was performed to place a cannula in a femoral artery for blood 
sampling. Also, a transmission scan was made for attenuation correction (515 s, with Co-57 





injected through the penile vein. A dynamic emission scan (76 min) was started during 
injection of radioactivity in the lower rat; the upper animal was injected 16 min later. A series 
of blood samples (14 samples; volume, 0.10–0.15 mL) was drawn, initially in rapid 
succession (every 15 s) and later at longer intervals (up to 30 min). Plasma was acquired from 
these samples by short centrifugation (Eppendorf centrifuge, 5 min at 13,000 
rpm).Radioactivity in 25 uL of plasma was counted and used as an arterial input function. 
Listmode data were reframed into a dynamic sequence of 8 x 30, 3 x 60, 2 x120, 2 x 180, 3 x 
300, 1 x 480, 2 x 600, and 1 x 960 s frames. The data were reconstructed per time frame using 
an iterative reconstruction algorithm (attenuation-weighted 2-dimensional ordered-subset 
expectation maximization, provided by Siemens; 4 iterations, 16 subsets; zoom factor 2). The 
final datasets consisted of 95 slices, with a slice thickness of 0.8 mm and an in-plane image 
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matrix of 128 * 128 pixels of size 1 * 1 mm. Datasets were fully corrected for random 
coincidences, scatter, and attenuation. Images were smoothed with a Gaussian filter (1.35 
mm in both directions). 
 
4.2.4 PET image data analysis 
 
Time–activity curves, volumes (mL) for the ROIs, partition co-efficient (K1/k2) and binding 
potential (BPND) by two-tissue reversible compartment model (2TCM) were calculated using 
the Siemens Inveon Research work place 4.0 (IRW 4.0). ROIs were drawn around the bulbus 
olfactorius, frontal cortex, striatum, amygdala, parietal/temporal/occipital cortex, medulla, 
cerebellum, pons and hippocampus in a template MRI scan that was co-registered with the 
PET scan of interest by image fusion. The cerebral distribution volume (VT) of the tracer was 
estimated from a Logan plot [21]. 
 
4.2.5 Biodistribution studies 
 
After the PET scan and 80 min after tracer injection, the anesthetized animals were 
sacrificed. Blood was collected, and plasma was obtained from the blood sample by short 
centrifugation (5 min at 1,000 x g). Several areas of the brain were dissected and peripheral 
organs were excised (see Table 2). The brain areas and peripheral organs were weighed and 
the radioactivity in these tissue samples was measured with a gamma counter, applying a 
decay correction. Tracer uptake was expressed as a dimensionless biodistribution SUV 
[tissue activity concentration (MBq/g)]/ [(injected dose (MBq)/body weight (g)]. 
 
4.2.6 A1R immunohistochemistry 
 
In a parallel experiment, male Wistar-Unilever rats were sham-infected or infected with 
HSV-1 as described above. On day 6 or 7, animals were terminated by deep anesthesia with a 
mixture of isoflurane/air (ratio 5%) and perfused intracardially with 150 ml of 0.9% saline 
followed by 250-300 mL of freshly prepared 4% paraformaldehyde in 0.1 M phosphate 
buffer (PBS), pH 7.4. The brain was removed and post-fixed in paraformaldehyde for 24 
h.The next day, the organ was embedded in paraffin. Coronal brain sections of 4 um were cut, 
using a microtome. Sections were collected on slides, dried in a hot air oven at 55°C 
overnight and then the tissue sections were ready for staining.  
In order to remove paraffin, the tissue sections were washed in xylene, 100, 96 and 
70% of ethanol and demi-water. For the antigen retrieval step, sodium citrate buffer (10mM 
sodium citrate) was added and the sections on the slides were boiled for 15-20 min in a 
microwave oven, followed by cooling down for 20-25 min and washing with PBS. The 
blocking step was carried out by adding 0.3% H2O2 in PBS to the slides, keeping them in this 
solution for 30 min followed by extensive washing with PBS and treatment with avidine and 
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biotine complex reagents for 30 min (Vectastain Elite ABC kit, Vector Laboratories), 
followed by 10% goat serum. The sections were incubated with primary antibody (Abcam 
rabbit polyclonal anti-A1 adenosine receptor diluted 1:100 in 1% bovine albumin solution in 
PBS) for 24 h at 4°C.Sections were then washed thoroughly with PBS and incubated in 
secondary antibody (Swine anti rabbit biotylated diluted in 1:300 in 1 % bovine albumin 
solution with PBS) for 30 min. After major rinsing of the sections in PBS, the tertiary 
antibody (streptavidine HRP diluted in 1:300 in 1 % bovine albumin solution with PBS) was 
added to the sections and incubation was continued for 30 min. As a negative control, 
sections were only incubated with secondary and tertiary (not the primary) antibody. The 
staining was visualized with 3,3’-diaminobenzidine (DAB) which was applied for 10 min. 
The sections were counterstained with haematoxylin for 1 min, and the stained sections were 
dehydrated with a graded series of ethanol and tap water (70, 96 and 99% ethanol). The final 
dehydration step was followed by drying, and mounting with Eulcitt (hardening medium) 
below a coverslip. Stained slides were examined using a microscope (Zeiss Axioskop 2, Carl 
Zeiss, Germany). 
 
4.2.7 Statistical tests 
 
Differences between groups were analyzed using 1-way ANOVA. A probability smaller than 





4.3.1 Animal model 
 
Disease symptoms were only observed after a delay of several days following HSV-1 
infection. Initial symptoms occurred usually at day 5 (irritated nose and eyes). More severe 
symptoms were seen on the scanning day (day 6 or 7); these included piloerection, a hunched 
posture and a sluggish response to stimuli. On the day of the PET scan, HSV-1-infected rats 
showed a significantly reduced body weight compared to sham-infected controls (267 ± 32 
vs 314 ± 30 g, p<0.02), reflecting a reduction of food intake. None of the animals reached the 
stage of advanced disease, since severe symptoms (seizures, complete paralysis, impaired 
breathing, and premature death) did never occur. Five animals reached score 1 and only two 
animals reached score 2. Thus, all animals were scanned in a relatively early phase of 
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 images of a HSV-1- and sham-infected animal are presented in Fig. 1. In both 
groups of animals the brain was clearly visualized. Tracer uptake was particularly high in 
hippocampus, cerebellum, striatum and some areas of the cortex, as observed previously in 





Figure 1. Small-animal PET images of rat brain acquired after injection of 
[
11
C]-MPDX  Sham-infected animal (left), HSV-infected animal (right). 
  
 
4.3.3 Time - activity curves in brain 
 
Time-activity curves for hippocampus, cerebellum and medulla are presented in Fig. 2. 
These brain areas are known to have a rather high A1R expression (hippocampus, 
cerebellum) (Chapter 2) and/or to be vulnerable to the viral infection [1,3,12,23]. Both in 
sham-infected and virus-infected animals, tissue uptake of radioactivity rapidly increased to 
a maximum which was followed by washout. However, uptake in the virus-infected animals 
was significantly greater than in sham-infected rats at intervals between 3 and 50 min. At 
intervals greater than 50 min, the difference in tracer uptake between healthy and diseased 
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Figure 2: Time-activity curves of [11C]-MPDX in three regions of rat brain. Standardized 
uptake values (PET-SUVs) are plotted as mean ± SEM. Solid symbols indicate data from 
sham infected animals, open symbols data from HSV-1 -infected rats.       
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4.3.4 Time - activity curves in plasma 
 





in both groups (Fig. 3). Infection of animals with HSV-1 did not significantly 
affect tracer clearance. Expressed as percentages of control, areas under the curve were 100 ± 




Figure 3: Time-activity curves of [
11
C] MPDX in rat plasma. Standardized uptake values 
(SUVs) are plotted as mean ± SEM. Solid symbols indicate data from HSV-1 infected 
animals, open symbols data from sham-infected rats. 
 
4.3.5 Graphical analysis of PET data 
 
Logan plots of the uptake of [
11
C]-MPDX in individual brain regions were similar to 
those presented previously for [
11
C]-MPDX uptake in the entire brain (Chapter 2). Logan VT 
of the tracer in the hippocampus and medulla of virus-infected rats was significantly 
increased (+37 and +40%, respectively) compared to the sham-infected controls (Table 1). In 




  106 
Table 1. Logan graphical analysis and 2 Tissue Compartment Model Fit of PET Data 
 
Data are listed as mean ± SD. NS = difference between groups not-significant. 
 
 
4.3.6 Compartment modeling 
 
A two-tissue compartment model with reversible tracer binding (2TCM) fitted well to time – 
activity curves from different ROIs in the brain, using radioactivity counts from arterial 
blood samples as an input function. Similar fits (for healthy rats) have been presented 




(ratio K1/k2 from the model 
fit) was not significantly affected by viral infection. However, BPND was significantly 
increased in cerebellum (+87%) and medulla (+148%) of virus-infected rats. BPND in 
hippocampus tended to be increased as well but this trend did not reach statistical 
significance due to a large variability in the infected group (Table 1). Animals with disease 
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in cerebellum, medulla 
and hippocampus of HSV-1- and sham-infected rats. Animals with a low disease score (score 
1) have higher BPND than animals which are really sick (score 2). 
 
 
4.3.7 Biodistribution data 
 




is presented in Table 2. 





was found compared to sham-infected rats. In peripheral organs, no significant 
changes in tracer uptake after viral infection were noted, with exception of a decreased 
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Mean tissue radioactivity 80 min after tracer injection listed as SUV ± SD. 





In the cerebellum of HSV-1-infected rats, we observed specific and strong A1R 
immunohistochemistry staining at different sites. Cerebellum from sham infected animals 
showed light A1R staining compared to cerebellum from HSV-1 infected animals (Fig. 5). 
IHC slides of HSV-1-infected rats showed intense staining in the dendritic tree and cell 
bodies of Purkinje cells. Cerebellar granule cells also exhibited strong staining. Astrocytes in 
the white matter showed weaker staining than Purkinje or granule cells although their 
staining was also increased compared to that observed in sham-infected rats. 
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A                              B 
 
    
 
C                               D 
       
   
 
Figure 5. Immunohistochemistry images of the cerebellum of sham-infected (panels A, B) 
and HSV-1-infected (panels C, D) rats. Panels A and C present an overview whereas panels 





4.5.1 MicroPET data 
 
Time-activity curves showed a significant increase of radioactivity uptake (PET-SUV) in 
several brain regions (hippocampus, cerebellum and medulla) of HSV-infected rats as 
compared to sham-infected controls (Fig. 1). Different mechanisms could be underlying this 
increased uptake, viz. changes of cerebral blood flow, greater blood-brain barrier 
permeability, upregulation of A1Rs or increased affinity of A1Rs for the radioligand. In order 
to clarify the mechanisms underlying increased tracer uptake, the PET data were analyzed by 
pharmacokinetic modeling. Partition coefficient of the tracer (K1/k2 from a 2TCM fit) was 
not significantly altered, but tracer distribution volume (VT estimated by 
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graphical Logan analysis) tended to be increased in several brain areas, statistical 
significance being reached in hippocampus and medulla (Table 1). Striking increases of 
tracer binding potential (BPND, k3/k4 from a 2TCM fit) were observed in cerebellum and 
medulla (Table 1). These modeling data suggest that the observed increases of tracer uptake 
are related to increases of the expression and/or the affinity of A1Rs for the radioligand rather 





plasma (Fig. 2) indicated that tracer delivery to the brain was not significantly different in 
HSV-1- and sham-infected rats.  
The HSV-1 encephalitis model which we employed has been examined previously with 
PET imaging. 
18
F-FHPG scans of the whole brain have indicated that replicating virus is 
present 7 days after infection [7]. 
18
F-FEAnGA scans detected increased expression of 
ß-glucuronidase in frontopolar and frontal cortex, bulbus olfactorius, cerebral cortex, 
cerebellum and brainstem [2]. Scans with translocator protein (TSPO) ligands indicated the 
presence of activated microglia in brainstem and cerebellum [11].  
Immunohistochemical techniques have also been used to characterize the HSV-1 
encephalitis model. The virus is known to move from the nasal mucosa to the brainstem via 
the trigeminal nerve and from the brainstem to the spinal cord via fiber connections. Six to 
seven days after the infection, viral antigen is detected in several brain areas (brain stem, 
amygdala, hippocampus, cerebellum, piriform and entorhinal cortex) and spinal cord but not 
in peripheral organs (lung, liver, spleen, kidney, adrenals). The virus is present both in 
neurons and glia [1, 3, 12, and 23]. The temporal and spatial pattern of inducible NO synthase 
expression, a marker of the neuroinflammatory response, coincide with those of viral 
propagation [12]. Loss of granule cells from the dentate gyrus in the hippocampus is noted in 
HSV-1 infected rats and may be responsible for memory deficits in humans following 
encephalitis [1]. 
Increases of tracer BPND in cerebellum and medulla which we noted in the present study 
may thus reflect upregulation of A1Rs in brain areas where active virus is present  
  
 
4.5.2 Biodistribution data 
 
The biodistribution study revealed a significant increase of tracer uptake only in pons 
and brainstem of the virus infected animals (31%, Table 2). No differences in other brain 
areas were noted, probably due to the fact that the biodistribution study was performed after 
the PET scan. A long interval had elapsed between tracer injection and tissue excision (80 
min); thus, the differences between the two groups had virtually disappeared (see Fig. 1). 
Moreover, variability in the biodistribution data was rather large since this interval 
corresponds to 4 half-lives of 
11
C. Increased tracer uptake in pons and brainstem may be 
related to viral invasion in trigeminal ganglia and principal sensory nucleus located in the 
brain stem [30]. 
                                                                       111 
4.5.3 Immunohistochemistry data 
 
Immunohistochemical analysis showed weak to normal staining of A1R in the cerebellum of 
sham-infected rats but intense staining in HSV-1-infected animals (Fig. 3). These data 
suggest that A1R are upregulated after viral infection. This upregulation may be 
neuroprotective and it seems to occur predominantly in neurons, particularly Purkinje cells. 
Increased expression and stimulation of A1R reduces neuronal excitability and may thus 
protect neurons from excessive stimulation. Neuroinflammation can be accompanied by 
release of the excitatory neurotransmitter glutamate [4,31] that may eventually cause 
neuronal death. On the other hand, increased expression and stimulation of A1R in cerebellar 
granule cells inhibits the release of glutamate and may thus contribute to neuroprotection 
[5,27]. Finally, activation of A1R on astrocytes and microglia may act as a brake on the 
inflammatory response [17]. Because of the combined action of these three mechanisms, 
activation of cerebral A1R is neuroprotective in animal models of Parkinson's disease [20], 





The present study demonstrated an upregulation of adenosine A1 receptor (A1R) in HSV-1 




and PET imaging. Data from our animals support the idea that upregulation of A1R occurs 
during the early (acute) phase of encephalitis and has a beneficial effect. The five animals 
with relatively low disease score (score 1) showed the highest values for tracer BPND in 
cerebellum, medulla and hippocampus, whereas the two rats with a higher disease score 
(score 2) showed a less striking increase of BPND (Fig.4). Thus, A1R upregulation and 
encephalitis symptoms may be inversely correlated. Additional studies are necessary to 
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Abstract 
 
Adenosine and adenosine analogs modulate BBB permeability in mice and rats through 
stimulation of A1 and A2A receptors. We performed a PET study to determine whether 
changes of BBB permeability after administration of A1 or A2AR agonists can be assessed 
by examining changes of the in vivo kinetics of hydrophilic radioligands. 
Methods: MicroPET scans combined with arterial blood sampling were made in three 
groups of isoflurane-anesthetized Wistar rats: (1) controls; (2) pretreated with A1R agonist 
CPA, dose 0.26mg/kg; (3) pretreated with A2A agonist Lexiscan, dose 0.05mg/kg. We used 
two hydrophilic radioligands i) the CXCR4 antagonist [
11
C]CH3-AMD3465 (clogP=-0.89) 
and ii) the dopamine agonist [
18
F]-AMC 15(clogP=1.54). Results: Administration of CPA 
(0.26 mg/kg) resulted in a strong (> 50%) and administration of Lexiscan in a moderate (< 
10 %) reduction of heart rate. We failed to observe BBB opening, as judged by tracer 
distribution volumes (VT) calculated from a Logan plot. Pretreatment of animals with CPA 
did not increase VT of [
11
C]CH3-AMD3465 (0.085 ± 0.052 vs. 0.135 ± 0.052 in controls). 
Also, no increment in VT of [
18
F]-AMC15 was noted after pretreatment of animals with 
CPA or Lexiscan (0.034 or 0.017 vs 0.035 in controls). Striatal binding of [
18
F]-AMC15 
was never observed. Conclusion: BBB opening could not be demonstrated by PET. Both 
radioligands failed to enter the rodent brain after pretreatment with an A1 or A2A agonist.  
 









The blood-brain barrier (BBB) is composed of endothelial cells [2] which line the 
microvasculature of the brain and are connected by tight junctions. These cells are 
functionally placed between brain and periphery. The BBB is divided into three sections: 1) 
the actual BBB, 2) blood-cerebrospinal fluid barrier, and 3) arachnoid barrier [1]. All three 
sections are involved in protection of the central nervous system by limiting the entry of 
toxic substances into the brain. Lipophilic molecules may pass the barrier in different ways. 
Small molecules can enter via i) ion channels ii) dissolving in the hydrophobic cell 
membrane followed by barrier passage by passive diffusion, and iii) facilitated transport. 
Such transporters may be either carrier-mediated or receptor-mediated [3]. Other 
transporters, like P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and 
breast cancer resistance protein (BCRP), are actually limiting substance entry into the brain 
by actively pumping molecules back to the blood after they have entered the brain by 
passive diffusion. The efficiency of the BBB is proven by the fact that more than 98% of all 
molecules with molecular weight greater than 500 Da do not enter the brain. With 
increasing prevalence of brain disorders there is an increasing demand for CNS drugs, but 
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many potential candidates fail to cross the barrier Thus, there is a need to modulate BBB 
permeability and facilitate the entry of therapeutic drugs into the CNS. 
Adenosine receptors are G-protein coupled and play several roles in mammalian physiology, 
including modulation of immune responses. Adenosine receptors can be divided in the A1R, 
A2AR, A2bR and A3R subtypes. Adenosine analogs can modulate BBB permeability in mice 
and rats through stimulation of A1R and A2AR receptors [4]. Activation of A1R and A2AR on 
brain endothelial cells causes cytoskeletal remodeling and changes in endothelial cells size 
and shape. Such stimulation appears to result in temporary opening of the tight junctions 
between the endothelial cells, allowing short-term entry of large molecules, like dextran or 
antibodies, into the brain [4]. 
         Thus far, no PET studies have been performed to assess changes of BBB 
permeability after administration of A1R or A2AR agonists. A PET assay for measurement of 
tight junction opening could employ a hydrophilic compound labeled with a positron 
emitter. Under normal conditions, such a compound will not enter the brain, but remains in 
the vascular compartment. After administration of a permeability-modulating drug (like the 
A1R agonist cyclopentyladenosine or the A2A agonist Lexiscan), the tracer may enter the 
brain resulting in a detectable PET signal. Uptake of radiolabeled compounds in the rodent 
brain can be quantified by calculating standardized uptake value (SUV), distribution 
volume (VT), or non-displaceable binding potential (BPND) of the radiotracer (see chapter 2 




5.2 Materials and Methods: 
 
5.2.1 (Radio) pharmaceuticals 
 
CPA and Lexiscan were purchased from Sigma (St.Louis, MO) and IDB Holland, 
respectively. The radioligand [
11
C]CH3-AMD3465 was prepared in the following way. 
[
11
C]Methane  was produced via the 
14N(p,α) 11C nuclear reaction by irradiating an 
N2+5 % H2 target gas with 17 MeV protons using a Scanditronix MC17 cyclotron. Typical 
beam currents were 5 to 8µA. [
11
C] CH3I was prepared from [
11
C] methane via procedures 
that were previously described in the literature [5]. [
11
C]Methyl triflate was formed by 
reacting [
11
C] methyl iodide with silver triflate bound on α-alumina using an on-line 
gas/solid exchange reaction at 240°C. [
11
C]Methyl triflate was transferred by a stream of 
helium (25ml/min) to a v-shaped reaction vial containing 0.4 mg of tri 
fluoroacetyl-AMD3465 in 300 μl acetone, cooled in an ice bath. After trapping of [11C] 
methyl triflate, the reaction mixture was heated at 80
0
C for 5 min.  Subsequently, 300µl of 
methanol and 100µl of NaOH (1M) were added and the reaction mixture was heated at 
80
0
C for another 5 min.  The reaction mixture was diluted with 0.6ml (16µl H3PO4) HPLC 
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eluent, and purified by HPLC using a Zorbax SB C18 (250x 7.8 mm) column with sodium 
phosphate buffer (pH 2.0)/EtOH (95/ 5 v/v %) as the eluent, at a flow rate of 4 ml/min. The 
radioactive product with a retention time of 12 ± 1 min was collected, neutralized with 1M 
NaOH  (~400 µl) and passed over a Millex 0.22-μm GV filter (Millipore, Ireland) to yield 
a sterile solution of N-[
11
C]methyl-AMD3465 ready for injection. The decay-corrected 
radiochemical yield of the tracer was 60 ± 2 % (n=20) and the total synthesis time was less 
than 50 min including the HPLC purification. An aliquot of this solution was analyzed by 
HPLC  using  a Jupiter  C18 column ( 300 x 7.8 mm, Phenomenex) and water (pH 2.0 )/ 
acetonitrile (90:10 v/v) as the eluent at a flow of 1 mL/min  (retention time: 8 ± 1 min). 




F]-AMC 15 was prepared by reaction of 2-[
18




F] fluoroethyl tosylate was purified by HPLC (Alltima C18 5u 250x10 mm column 
eluted with acetonitrile/10 mM sodium acetate buffer pH 4.0 (60/40 v/v) at 5 ml/min (tR = 
6.8 min, k’= 3.8)). At the end of the deprotection step, the reaction mixture was diluted with 
10 ml water, titrated with 1 M NaOH to pH of 4 to 7 and then put through an Oasis HLB 
SPE cartridge. Adsorbed activity was eluted from the cartridge with 1 ml acetonitrile/DMF 
(1/1 v/v). The eluate was further diluted with water to a total volume of 1.5 to 2 ml and 






F]AMC 15 was purified using an Alltima C18 5u 250x10 mm column eluted with a 
gradient of acetonitrile in 10 mM sodium acetate buffer: isocratic 45% acetonitrile during 
the first 2 min, then a linear decrease from 45 % at 2 min to 30% acetonitrile at 15 min 
(retention time of [
18
F] AMC15 is 10.6 min, k’ = 5.9). HPLC conditions for the identity 
confirmation and RCP assessment were: Platinum EPS 5u 250x4.6 column eluted with 
acetonitrile/10 mM phosphate buffer pH 7 (65/35 v/v) at 2 ml/min (tR = 11.0 min, k’ = 7.3). 
Quality control TLC conditions were: dichloromethane: methanol: ammonia 100:5:1 (Rf = 
0.25) and ethyl acetate: methanol: ammonia: triethylamine 100:5:5:1 (Rf = 0.3). Before 
putting radioactive samples onto the TLC plates, drops of AMC 15 oxalate standard 
solution containing 2 μg of compound were put onto the start positions of each lane to 





5.2.2 Experimental Animals 
 
All animal experiments were performed by licensed investigators in compliance with the 
Law on Animal Experiments of The Netherlands. The protocol was approved by the 
Committee on Animal Ethics of University of Groningen. Male outbred Wistar-Unilever 
(SPF) rats (body weight 304 ± 54 g) were obtained from Charles-River, maintained at a 
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12-h light/12-h dark regime and fed standard laboratory chow ad libitum. Three groups of 
animals were studied for [
11
C]CH3-AMD3465: 1) Controls (pretreated with saline, i.p., n 
=3); 2) Animals pretreated with CPA (0.25 mg/kg, i.p., dissolved in 0.3 mL saline 
containing < 50 µL dimethyl sulfoxide, n = 2, see [6]; 3) Animals pretreated with Lexiscan 
(0.05 mg/kg, i.v., dissolved in saline, n = 1). Three groups of animals were studied for 
[
18
F]-AMC 15: 1) Controls (pretreated with saline, i.p., n = 1; 2) Animals pretreated with 
CPA (0.25 mg/kg, i.p., dissolved in 0.3 mL saline containing < 50 µL dimethyl sulfoxide, n 
= 1 see [6] 3) Animals pretreated with Lexiscan (0.05 mg/kg, i.v., dissolved in saline, n = 1); 
The very small number of animals in each group is due to the fact that this study is a pilot 
which was still ongoing by the time the PhD thesis was written 
 
5.2.3 PET scanning 
 
Two rats were scanned simultaneously, using a Focus 220 microPET camera 
(Siemens-Concorde, Knoxville, TN). Animals were anesthetized with a mixture of 
isoflurane/air (ratio 5% during induction, later reduced to ≤ 2%).  Cannulas were placed in 
a femoral artery and vein for blood sampling and tracer injection, respectively. A 
transmission scan was made, using an external source of radioactive cobalt, in order to 




F]-AMC 15 emission images 
for attenuation and scatter. Rats were under anesthesia for 30–40 min before tracer injection 





F]-AMC 15 in volume of 1 mL) were injected through the venous cannula, as a slow (1 
min) bolus, using a Harvard-style pump. The camera was started as soon as the tracer 
entered the body of the first rat in the scanner; the second animal of the pair was injected 16 
min later. Scanning was then continued for another 60 min. The animal that was injected 
last was also anesthetized at a later moment. Thus, the duration of anesthesia was similar in 
all study groups. A list-mode protocol was used (76 min, brain in the field of view). A series 
of blood samples (18 samples; volume, 0.10–0.15 mL) was drawn, initially in rapid 
succession (5 s) and later at longer intervals (up to 30 min). Plasma was acquired from 
these samples by centrifugation (Eppendorf centrifuge, 5 min at 13,000 rpm). Radioactivity 
in 25 µL of plasma and 25 µL of whole blood was counted and used as an arterial input 
function. During the entire scanning procedure, heart rate, stroke volume and blood oxygen 
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5.2.4 Analysis of PET Data 
 
List-mode data were reframed into a dynamic sequence of 8 × 30, 3 × 60, 2 ×120, 2 × 180, 
3 × 300, 1 × 480, 3 × 600, and 1 × 960 s frames. The data were reconstructed per time 
frame using an iterative reconstruction algorithm (attenuation-weighted 2-dimensional 
ordered-subset expectation maximization, provided by Siemens; 4 iterations, 16 subsets; 
zoom factor 2). The ﬁnal datasets consisted of 95 slices, with a slice thickness of 0.8 mm 
and an in-plane image matrix of 128 ×128 pixels of size 1.1 mm. Datasets were fully 
corrected for random coincidences, scatter, and attenuation. Images were smoothed with a 




) for the regions of interest (ROIs) were calculated using the Siemens Inveon 
Research Work Place 4.0 (IRW 4.0). ROIs were drawn around the (entire) bulbi olfactorii, 
frontal cortex, striatum, amygdala, parietal/temporal/occipital cortices, medulla, cerebellum, 
pons and hippocampus in a template MRI scan that was co-registered with the PET scan of 
interest by image fusion (17). Standardized uptake values measured by PET (PET-SUVs) 
were calculated, using measured body weights and injected doses [tissue activity 
concentration (MBq/mL)]/[(injected dose (MBq)/body weight (g)]. The cerebral 
distribution volume (VT) of the tracer was estimated either from a Logan plot or a 
2-tissue-compartment model (2TCM) fit. The partition coefficient (K1/k2) and binding 










5.3.1 Small-Animal PET Images  
 





F]-AMC15 . Neither in control animals, nor in animals pretreated with CPA or Lexiscan 
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5.3.2 Graphical Analysis of PET Data 
 
Tracer VT was calculated using a Logan plot, time–activity curves from an ROI drawn 
around the entire brain, and radioactivity counts from arterial blood samples. There was no 
increase in VT of [
11
C]CH3-AMD3465 after pretreatment of animals with CPA compared to 
controls (0.085 ± 0.052 vs 0.135 ± 0.052, respectively). Also no increment in VT of 
[
18
F]-AMC15 was observed after pretreatment of animals with CPA or Lexiscan compared 




5.3.3 Compartment Modeling of PET Data 
 
When a 2TCM was fitted to time–activity curves from a ROI drawn around the entire brain, 





F]-AMC15 (ratio K1/k2 from the model fit) were 
found not to be affected by CPA or Lexiscan (Table 4 and 5) . The ratio of k3/k4, a measure 
of tracer binding potential, for [
11
C]CH3-AMD3465 remained unaltered after pretreatment 
with the A1R or A2AR agonist (Table 4). k3/k4 of [
18
F]-AMC 15 appeared to show some 
increase after pretreatment with the A1 agonist but was unaltered after treatment with the 




5.3.4 Biodistribution Data 
 




F]-AMC15, acquired 80 min after 
injection of [
11
C]CH3-AMD 3465 and [
18
F]-AMC15, are presented in Table 1 and 2. 





F]-AMC 15 uptake in brain areas and peripheral organs 
 
 
5.3.5 Physiological response  
 
After i.p. administration of the A1 agonist CPA a very strong decline of heart rate was 
observed within 5 min (from 340 to about 100) and after i.v injection of A2A agonist 
Lexiscan, we also noticed decline of heart rate (from 340 to 320). 
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Table 1: Biodistribution Data of [11C]CH3-AMD3465, 80 minutes after Injection 
 
Tissue Control 
animals (n = 3) 
Treated with 
0.26mg/kgCPA 
(n = 1) 
Lexiscan 
0.05mg/kg (n = 
1) 
Brain 1 0.208 ± 0.047 0.179 0.075 
Brain 2 0.532 ± 0.136 0.126 0.107 
Bone 0.518 ± 0.099 0.304 0.297 
Colon 0.574 ± 0.195 0.937 0.549 
Duodenum 1.304 ± 0.150 0.226 0.693 
Fat 0.488 ± 0.122 1.420 0.261 
Heart 0.820 ± 0.204 0.140 0.418 
Ileum 1.436 ± 0.133 28.232 0.358 
Kidney 11.180 ± 5.351 9.976 9.928 
Liver 10.990 ± 3.665 1.203 8.210 
Lung 0.437 ± 0.274 0.110 0.769 
Muscle 0.463 ± 0.077 0.716 0.205 
Pancreas 0.7320 ± 0.120 1.814 0.307 
Plasma 1.121 ± 0.563 0.863 0.257 
Red cells 0.768 ± 0.235 1.823 0.506 
Spleen 1.560 ± 0.433 1.449 0.757 
Urine 4.779 ± 1.820 0.131 25.024 
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Table 2: Biodistribution Data of [
18
F]-AMC 15, 80 Minutes after Injection 
 
Tissue Control 
animals (n = 1) 
Treated with 
0.26mg/kgCPA 
(n = 1) 
Lexiscan 
0.05mg/kg (n = 
1) 
Brain 1 0.082 0.065 0.035 
Brain 2 0.059 0.069 0.026 
Brain 3 0.075 0.057 0.035 
Bone 0.151 0.664 0.205 
Colon 0.822 0.401 0.327 
Duodenum 1.702 12.670 9.241 
Fat 0.251 0.196 0.113 
Heart 0.113 0.565 0.240 
Ileum 0.263 0.567 1.114 
Kidney 0.367 2.928 1.168 
Liver 1.119 1.651 2.052 
Lung 1.229 5.572 2.842 
Muscle 0.076 0.291 0.164 
Pancreas 0.617 3.489 0.999 
Plasma 0.097 0.223 0.200 
Red cells 0.037 0.104 0.081 
Spleen 1.427 2.157 1.564 
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Tissue Control animals 
(n = 1) 
Treated with CPA 
(n = 1) 
Amygdala 0.094 0.095 
Olfactory bulb 0.211 0.167 
  Cerebellum 0.170 0.246 
Cingulate 0.717 0.235 
Entorhinal 0.244 0.132 
Frontal 0.178 0.097 
Hippocampus 0.083 0.152 
Medulla 0.360 0.149 






Pons 0.234 0.095 
Striatum 0.134 0.065 
Rest of the brain 0.172 0.095 
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5.4 Discussion 
 
This ongoing project aimed to answer the question whether transient opening of the 
blood-brain barrier after treatment of animals with adenosine receptor agonists can be 
detected with hydrophilic radiotracers and PET. Such tracers do not pass the normal barrier, 
but may pass after BBB opening. 
 
For initial attempts we used [
11
C]CH3-AMD3465 (CXCR4 antagonist) and [
18
F]-AMC15 
ligand (dopamine D2 agonist). The clogP of [
11
C]CH3-AMD3465 is -0.89 and [
18
F]-AMC15 
is 1.54. But the preliminary PET data and microPET images showed no differences in brain 
uptake between animals treated with adenosine receptor agonists and untreated controls. A 
biodistribution study, performed 80 min after tracer injection, also did not indicate any 
increases of radioactivity in the brain of pretreated animals. A 2TCM was fitted to 
time–activity curves from a ROI drawn around the entire brain, using radioactivity counts 
from arterial blood samples as input function. This kinetic modeling approach indicated that 
neither the partition coefficient (K1/k2) nor the binding potential (k3/k4) of 
[
11
C]CH3-AMD3465 were affected by the treatment but k3/k4 of [
18
F]-AMC 15 seemed 
increased after pretreatment with the A1 agonist CPA, whereas K1/K2 remained unchanged. 
Since this increase is based on the analysis of data of just a single animal and did not result 
in visibility of the striata in microPET images, the modeling result may not be significant. 
Extremely low values for tracer partition coefficient suggested that the tracer did never pass 
the blood-brain barrier (Table 5). 
 
According to Carman et al. [4], transient BBB opening should occur after treatment of 
animals with an A1R or A2AR agonist and should persist for several hours. In our 
experiments, the agonists were administered properly as proven by strong physiological 
responses of the rats (decline of heart rate, increase of stroke volume). However, we could 
not detect any BBB opening with PET. We failed to observe hydrophilic tracer uptake in rat 
brain after pretreatment with A1 and A2A agonists. This negative finding could be related to 
different underlying mechanisms:  
 
1. Hydrophilic tracers may be rapidly cleared from the circulation (i.e., within 5 or 10 min 
after injection) whereas opening of the barrier may occur only later, after a prolonged 
interval (e.g., more than 20 min after agonist administration). Thus the barrier would open 
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2. Because of certain physiological conditions of the animals during the scanning procedure 
(anesthesia, acidosis, hypercapnia or hypothermia) the BBB may not have opened after 
pretreatment with an A1R or A2AR agonist. In the published study describing barrier 
opening [4], animals were only anesthetized at the end of the experiment for the purpose of 
euthanasia.  
 
In a follow-up study, we plan to test our experimental procedure with a widely used and 
generally accepted assay for BBB permeability, the Evans Blue assay. This assay can 
answer the question whether the BBB was in fact opened, or did not open at all. It is 
important to know whether the failure of the PET assay was due to inappropriate tracer 
kinetics (mechanism 1) or failure of the experimental animals to respond to the 




Table 4: Results from Graphical Analysis and Compartment Modeling of PET Data 




Group VT (Logan)  K1/k2 (2TCM) BPND (k3/k4) 
(2TCM) 
Control (n=3) 0.352±0.052 0.046±0.011 2.822±1.055 
CPA (n=2) 0.116±0.012 0.033±0.003 2.187±0.619 





Table 5: Results from Graphical Analysis and Compartment Modeling of PET Data 




Group VT (Logan)  K1/k2 (2TCM) BPND (k3/k4) 
(2TCM) 
Control (n=1) 0.0349 0.0001 7.4381 
CPA (n=1) 0.0344 0.0001 12.635 
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5.5 Conclusion 
 





F]-AMC15 we could not demonstrate BBB opening after adenosine receptor stimulation. 
Both tracers did not enter the brain after pretreatment of rats with A1 or A2A agonists. 
Further studies are necessary to determine whether this negative finding is due to 
inappropriate kinetics of the tracers or failure of anesthetized animals to respond to 
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Adenosine is a neuromodulator with several functions in the central nervous system (CNS), 
such as inhibition of neuronal activity in many signaling pathways. The adenosine receptor 
(AR) family consists of the A1, A2A, A2B and A3 subtypes (A1R. A2AR, A2BR and A3R, 
respectively). A1R and A3R inhibit whereas A2AR and A2BR stimulate production of the 
second messenger, cAMP. Adenosine A1 receptors (A1R) stimulation may result in 
neuroprotection and suppression of neuroinflammation. 
 
Positron Emission Tomography (PET) is a powerful in vivo imaging tool which can be 
applied to investigate the physiologic and pathologic roles of A1R in the human and rodent 
brain. Several ligands for PET imaging of A1R have been prepared. The best-characterized 
tracers are [
11
C] MPDX and [
18
F] CPFPX. Both can be applied for PET studies of cerebral 
A1R in humans.  
 







C]-methyl-3-propyl-xanthine) for preclinical studies of A1R in 
rodent brain – including use of the tracer to determine the regional pattern of A1R 
expression, changes of expression as a consequence of disease and the dose-dependent 
occupancy of cerebral A1R by non-radioactive agonists and antagonists. 
 
Chapter 1 provides an introduction to adenosine A1R imaging and discusses roles of A1R 
in health and disease. In Chapter 2, we applied [
11
C]-MPDX for visualization of A1R in rat 
brain. High uptake of radioactivity was noted in striatum, hippocampus, and cerebellum. 
Specific binding of the tracer in individual brain regions corresponded closely to regional 
A1R densities known from autoradiography (see Figure 5 in Chapter 2). Pretreatment of 
animals with the selective A1R antagonist DPCPX resulted in a strong suppression of tracer
  
binding and regional differences of uptake were abolished. Raising levels of the 
endogenous agonist, adenosine, by treating rats with a 20% solution of ethanol in saline (2 
mL) plus the adenosine kinase inhibitor 4-amino-5-(3-bromophenyl)-7-(6-morpholino- 
pyridin3-yl) pyrido [2,3-d] pyrimidine dihydrochloride (ABT-702) did not result in 




for binding to A1R, but rather in an 
unexpected global increase of the cerebral uptake of radioactivity (by 40% to 45%). Kinetic 
modeling suggested that this increase is not related to altered blood flow or altered 
blood-brain barrier passage of the radioligand, but rather to increased binding at the 
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In Chapter 3 we examined whether A1R occupancy by therapeutic drugs (non-radioactive 




and PET. As an A1R agonist we 
used N
6
-cyclopentyladenosine (CPA, 0.25mg/kg, i.p) and as an A1R antagonist caffeine (4 
and 40 mg/kg, i.p.). Administration of CPA resulted in a strong reduction (>50%) of heart 
rate, and caffeine administration in a small increase (10-15%). The low dose of caffeine 
resulted in 65.9% A1R occupancy and the high dose in 98.5% occupancy, as calculated by a 
modified Lassen plot. Administration of CPA did not result in measurable competition of 
the agonist with [
11
C]MPDX for binding to A1R in the brain, but rather in a paradoxic 
increase of tracer uptake similar to the increase we noticed after raising the level of 
endogenous adenosine (Chapter 2). Kinetic modeling of tracer binding suggested that 
adenosine analogs may increase the fraction of A1R that can bind the radioligand. Thus, 
[
11
C]MPDX is a suitable tracer for determining occupancy of A1R by non-radioactive 
xanthine antagonists but not purine agonists. 
 
In Chapter 4 we assessed changes of A1R expression in a rat model of encephalitis. Wistar 
rats were intranasally infected with herpes simplex virus-1 and scanned after an interval of 
six or seven days when they began to show the symptoms of cerebral inflammation. 
Regional distribution volumes of [
11
C]MPDX (VT) calculated from a Logan plot indicated 
significant increases of tracer uptake in hippocampus and medulla of virus-infected rats. A 
2-tissue compartmental model fit of the microPET data indicated significant increases of 
tracer binding potential in hippocampus, cerebellum and medulla which may indicate 
increased A1R expression. The partition coefﬁcient of [
11
C]-MPDX (ratio K1/k2 from the 
model ﬁt) was not signiﬁcantly altered after virus infection. Immunohistochemical staining 
showed a strong increase of A1R immunoreactivity in cerebellum of HSV-1-infected rats. 
These data indicate an upregulation of adenosine A1 receptors (A1R) in the early phase of 





imaging. This upregulation may limit the release of excitatory neurotransmitters such as 
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In Chapter 5 we investigated whether transient opening of the blood-brain barrier after 
treatment of animals with (non-radioactive) adenosine A1 and A2A receptor agonists can be 
detected with hydrophilic radiotracers and PET. Such tracers do not pass the intact barrier, 
but may pass after BBB opening. For our initial pilot, we used [
11
C]CH3-AMD3465 
(CXCR4 antagonist) and [
18
F]AMC 15 (Dopamine D2 receptor agonist). Cerebral uptake 
(SUV) and distribution volume (VT) of both tracers was not increased after pretreatment of 
animals with CPA or Lexiscan. Further studies are necessary to determine whether this 
negative finding is due to inappropriate kinetics of the used tracers or to lack of blood-brain 
barrier opening in anesthetized rats. 
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Conclusion 
 
1. [11C]MPDX and PET can be used to assess regional adenosine A1R expression in the 
rodent brain (Chapter 2). Regional distribution volume (VT) from a Logan plot or 
k3/k4-ratio from a two-tissue compartment model may be used to quantify [
11
C] MPDX 
binding to A1R.  
 
2. Occupancy of A1R by non-radioactive xanthines (antagonists) can be assessed with [
11
C] 
MPDX and PET (Chapters 2 and 3). 
 
3. However, occupancy of A1R by non-radioactive agonists (adenosine, CPA, i.e. purines)   
can not be assessed with this technique. This may be due to the fact that adenosine analogs 
and xanthine antagonists bind to different domains of the A1R which show allosteric 
interactions, or adenosine analogs increase the fraction of A1R that can bind the radioligand  
(Chapters 2 and 3). 
 
4. Herpes-simplex virus-induced encephalitis is associated with an upregulation of A1R in 
several brain areas (cerebellum, hippocampus, pons/midbrain, and medulla). This         
upregulation appears to occur particularly in the early - or acute - phase of viral      
inflammation. A1R upregulation may protect neurons against excessive stimulation by    
excitatory neurotransmitters such as glutamate (chapter 4). 
 
5. Blood-brain barrier opening could not be demonstrated using two hydrophilic tracers (the 
CXCR4 receptor antagonist [
11
C]CH3-AMD3465 or dopamine D2 receptor agonist 
[
18
F]-AMC 15) and small animal PET. We did not observe any tracer uptake in rat brain 
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Future Perspectives 
Data presented in this thesis show that the PET tracer [
11
C] MPDX can be used to visualize 
regional A1R expression in the rodent brain (chapter 1) and to assess changes of A1R 
binding as a consequence of disease (chapter 4). Occupancy of cerebral A1R by 
non-radioactive xanthine antagonists (but not purine agonists) is measurable with [
11
C] 
MPDX and PET (chapters 1, 3). In future studies, the PET tracer may be applied to answer 
several interesting research questions  
 
Impact of anesthetics 
Based on findings reported in the literature, we expect that anesthesia has an impact 
on the measured (apparent) A1R densities in rodent brain. At anesthetic dose, halothane 
inhibits the binding of an A1R agonist by 20-30% (1). On the other hand, A1R may be 
involved in some actions of anesthetics and in known interactions between anesthetics and 
recreational drugs such as ethanol. Adenosine is formed during the metabolism of ethanol, 
which results in stimulation of A1R (2-4) and potentiation of isoflurane anesthesia (2). 
Halothane anesthesia is potentiated after treatment of animals with the A1R agonist 
L-phenylisopropyladenosine (L-PIA); such treatment reduces the minimum anesthetic 
concentration (MAC) of halothane by 49% (5).  The expression of the enzyme ecto 
5’-nucleotidase (CD73) which is responsible for the formation of extracellular adenosine by 
converting extracellular AMP to adenosine is increased by isoflurane (6). Neuroprotective 
effects of isoflurane (e.g. after cerebral injury) (7) and cardioprotective effects of fentanyl 
(8) and desflurane (9) during myocardial ischemia may be related to A1R stimulation, since 
some of these beneficial effects could be prevented by co-administration of an A1R 
antagonist (8).  
In future experiments, animals could be anesthetized with different anesthetics 




in awake and anesthetized 
animals could be compared, in order to study the impact of anesthesia on apparent A1R 
expression. We expect changes of [
11
C] MPDX binding as a consequence of anesthesia. To 
gain more insight in the mechanisms underlying the impact of anaesthetics, therapeutics or 
recreational drugs on the in vivo binding of [
11
C] MPDX, microPET scans could be 
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Neuroinflammation 
Additional studies are necessary to further characterize the role of A1R signaling in rodent 
neuroinflammation. We have examined only a single inflammation model (virus-induced), 
involving a rather acute form of inflammation. Also, we could scan only a limited number of 
animals. Our data suggest that A1R upregulation may be transient and limited to the early 
phase of encephalitis, but we have not actually proven this (see chapter 4). In future 
experiments, the impact of acute and chronic inflammation on adenosine A1R expression 
could be compared. We expect an upregulation of A1R in the acute phase and a 
downregulation in the chronic phase of neuroinflammation, as acute inflammation induced 
by injection of lipopolysaccharide (11) was associated with an upregulation of A1R in mouse 
brain (12) whereas chronic experimental allergic encephalomyelitis (EAE) was associated 
with a downregulation of A1R (13). 
 
Traumatic brain injury 
Adenosine and A1R are involved in the suppression of neuronal hyperactivity and 
limitation of the inflammatory response after traumatic brain injury. When normal and A1R 
knockout mice were subjected to controlled cortical impact, seizure scores were much higher 
in the knockouts and only knockout animals developed lethal status epilepticus [14]. 
Similarly, unilateral hippocampal kainate injection caused nonconvulsive status epilepticus 
in wild-type mice but severe convulsions and subsequent death in A1R knockouts [15]. Status 
epilepticus is associated with widespread release of adenosine throughout the brain and 
suppression of the excitability of neurons remote from the epileptic focus via stimulation of 
A1R. In A1R knockout mice, this protective mechanism is lacking, so that severe convulsions 
and lethal status epilepticus can develop [15]. A1R knockout mice display a 20-50% 
enhanced microglial response after mild traumatic brain injury compared to their wild-type 
littermates. Stimulation of A1R in immortalized mouse microglia (BV-2) cells results in 
inhibition of microglial proliferation [16]. Thus, longitudinal microPET studies with [
11
C] 
MPDX in a rat model of traumatic brain injury could be an interesting research project. A1R 
expression may be different shortly and several weeks after controlled cortical impact. In a 
rat model of acute general seizure (i.p. injection of a convulsive dose of bicuculline), a 
widespread increase of A1R expression was noted [17] but in animal models of chronic 
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Chronic sleep deprivation 
Many endogenous factors are involved in maintenance of sleep-wake cycle, one of these is 
adenosine which reduces wakefulness by activation of A1R in pre- and postsynaptic regions, 
resulting in inhibition of the release of excitatory neurotransmitters and dampening of the 
response of neurons to these signals (21). A1Rs are known to be involved in homeostatic 
sleep regulation. An increment in cerebral A1R expression was noted both in animals (22-25) 
and humans (26) after acute sleep deprivation. Short periods of total sleep deprivation (3 or 6 
h) result in increases of A1R mRNA but no detectable increases of A1R expression in rat brain 
[22]. However, longer periods of total sleep deprivation in rodents (12 or 24 h) are 
accompanied by a significant upregulation of A1R (up to 14%) in several brain areas [23, 24]. 
Saturation binding assays have indicated that A1R densities in cortical and subcortical 
regions of rat brain are increased not only after total sleep deprivation, but also after 48 and 
96 h of partial, rapid eye movement (REM) sleep deprivation, whereas affinity (Kd) values 
for agonist ([
3
H]PIA) binding are not significantly altered (25). Most reported studies about 
involvement of A1R in sleep have examined the impact of acute, total sleep deprivation. In 
future, longitudinal PET studies the impact of various intervals (2 days, 5 days, 30 days) of 
severe sleep deprivation (20 hrs/day) could be directly compared. Such studies might answer 
the question whether acute and chronic sleep deprivations have different effects, and if the 
upregulation of A1R is transient or permanent. 
 
 
Animal models of anxiety 
Adenosine and A1R may be involved in the control of anxiety. Mice lacking A1R show 
increased anxiety-like behavior compared to normal mice (27). Moreover, selective A1R 
agonists (like 2-chloro-N (6)-cyclopentyladenosine, CCPA) have anxiolytic effects both in 
mice (28) and rats (29). Anxiety-like behavior in mice during acute ethanol withdrawal is 
weakened after acute administration of CCPA (30). Chronic treatment of mice with the A1R 
antagonist DPCPX results in upregulation of A1R and reduced exploratory behavior, which 
is suggestive of reduced anxiety (31). No PET study has ever been performed to assess 
regional differences of cerebral A1R expression in anxiety-prone and normal rodents, or 
changes of cerebral A1R expression after stress-induced anxiety. In the latter case, a modest 
upregulation of A1R may be expected, since a 15% increase of A1R density in hypothalamic 
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Human studies 
Besides the preclinical studies in rodents proposed above, PET studies in humans are 
possible and could be focused on the role of A1R in the following disorders of the brain. 
 
1. Multiple sclerosis (MS).  
A1R densities and the coupling of A1R to cytokine signaling systems appear to be altered in 
MS. A1R numbers in peripheral blood mononuclear cells (PBMC) and in brain tissue from 
MS-patients are significantly decreased (by 53% and 49%, respectively) compared to 
age-matched controls (33). Plasma levels of TNF-alpha in such patients are significantly 
higher and levels of adenosine are significantly lower than in control subjects. Stimulation of 
PBMC with a selective A1R agonist (R-PIA) inhibits the mitogen-stimulated production of 
TNF-alpha in healthy subject but not in MS patients, whereas the opposite is observed for the 
mitogen-stimulated production of interleukin-6 (34) PET studies with A1R ligands in MS 
patients and age-matched controls have not yet been performed. Based on post mortem 




A partial loss of A1R during birth and a corresponding reduction of the control of dopamine 
activity in later life has been proposed to play a role in the inhibitory deficit in schizophrenia 
(35, 36). In a Japanese population, schizophrenia was found to be associated with a single 
nucleotide polymorphism of the A1R gene (rs3766553) (37). PET studies of cerebral A1R in 
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SAMENVATTING 
 
Adenosine is een neuromodulator met uiteenlopende functies in het centraal zenuwstelsel, 
zoals inhibitie van neuronale activiteit in vele signaalroutes. De adenosine receptor (AR) 
familie bestaat uit de subtypes A1, A2A, A2B en A3 (afgekort als A1R, A2AR, A2BR en A3R). 
A1R en A3R remmen de vorming van de ―second messenger‖ cyclisch AMP, terwijl A2AR 
en A2BR deze vorming stimuleren. Activatie van adenosine A1 receptoren (A1R) kan leiden 
tot bescherming van neuronen en tot onderdrukking van neuroinflammatie. 
 
Positron Emissie Tomografie (PET) is een krachtige techniek voor in vivo imaging die kan 
worden toegepast om de (patho)fysiologische betekenis van A1R in het brein van 
knaagdieren en mensen beter te gaan begrijpen. Er zijn meerdere liganden voor PET 




F]CPFPX zijn daarvan het best 
gekarakteriseerd. Beide liganden kunnen worden toegepast voor PET studies van A1R in het 
menselijk brein. 
 





C]-methyl-3-propyl-xanthine) voor preklinische studies van 
A1R in het knaagdierbrein. Dit houdt in: gebruik van de tracer om het regionale patroon van 
A1R expressie en veranderingen van deze expressie ten gevolge van ziekte vast te stellen, 
plus de dosis-afhankelijke bezetting van A1R door niet-radioactieve agonisten en 
antagonisten. 
 
Hoofdstuk 1 verschaft een inleiding tot imaging van A1R en bespreekt de rol van A1R in 
het gezonde en zieke brein. In hoofdstuk 2 hebben wij [
11
C]MPDX toegepast om A1R in 
het rattenbrein te visualiseren. Een hoge opname van radioactiviteit werd waargenomen in 
striatum, hippocampus en cerebellum. De specifieke binding van de tracer in individuele 
hersengebieden kwam overeen met regionale dichtheden van de A1R zoals die bekend zijn 
uit autoradiografie (zie Figuur 5 in hoofdstuk 2). Voorbehandeling van proefdieren met de 
selectieve A1R antagonist DPCX resulteerde in een sterke onderdrukking van de 
tracerbinding en regionale verschillen in opname waren niet langer aanwezig. Indien de 
niveaus van de endogene agonist adenosine werden verhoogd, door ratten voor te 
behandelen met een oplossing van 20% ethanol in fysiologisch zout (2 ml) plus de 
adenosine kinase remmer 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin3-yl) pyrido 
[2,3-d] pyrimidine dihydrochloride (ABT-702) leidde dit niet tot meetbare competitie van 
adenosine met [
11
C]MPDX voor binding aan A1R, maar tot een onverwachte globale 
verhoging (40 tot 45%) van de opname van radioactiviteit in het brein. Door 
tracer-kinetisch modelleren werd de indruk gewekt dat deze toename niet was te wijten aan 
veranderde doorbloeding of een veranderde permeabiliteit van de bloed-hersenbarrière, 
maar aan een toename van de tracer binding op het niveau van de receptor. 
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In hoofdstuk 3 onderzochten we of de bezetting van A1R door geneesmiddelen 
(niet-radioactieve agonisten en antagonisten) met behulp van [
11
C]MPDX en PET kan 
worden vastgesteld.  Als A1R agonist gebruikten we N
6
-cyclopentyladenosine (CPA, 0.25 
mg/kg, i.p.) en als A1R antagonist caffeïne (4 en 40 mg/kg, i.p.). Toediening van CPA 
resulteerde in een sterke afname (> 50%) van de hartslag, en toediening van caffeïne in een 
kleine toename (10 tot 15%). De laagste dosis caffeïne resulteerde in 65.9% bezetting van 
de A1R populatie en de hoogste dosis in 98.5%, berekend via een Cunningham-Lassen plot. 
Toediening van CPA leidde niet tot meetbare competitie van de agonist met [
11
C]MPDX 
voor binding aan A1R in het brein, maar in een paradoxale toename van de traceropname 
die vergelijkbaar was met de toename die we eerder hadden waargenomen na verhoging 
van het niveau van endogeen adenosine (Hoofdstuk 2). Door kinetisch modelleren van de 
tracer binding werd de indruk gewekt dat adenosine analoga de fractie van de A1R 
populatie die het radioligand kan binden kunnen verhogen. [
11
C]MPDX is dus een 
geschikte tracer om de bezetting van A1R door niet-radioactieve antagonisten vast te stellen, 
maar de bezetting van de receptorpopulatie door agonisten kan niet worden vastgesteld. 
 
In hoofdstuk 4 schonken we aandacht aan veranderingen van de expressie van A1R in een 
diermodel van encephalitis. Wistar ratten werden via de neus geïnfecteerd met herpes 
simplex virus-1 en gescand na een interval van zes of zeven dagen, wanneer ze de 
symptomen van hersenontsteking begonnen te vertonen. Het regionale distributievolume 
van [
11
C]MPDX in hippocampus en medulla van geïnfecteerde ratten bleek significant te 
zijn verhoogd (VT berekend uit een Logan plot). De bindingspotentiaal van het radioligand 
(k3/k4 berekend op grond van de fit van een model met 2 weefselcompartimenten) bleek in 
hippocampus, cerebellum en medulla significant te zijn toegenomen, wat op verhoogde 
expressie van A1R zou kunnen wijzen. De partitiecoëfficiënt (K1/k2) van [
11
C]MPDX  was 
echter niet significant gewijzigd na virusinfectie. Immunohistochemische kleuring liet een 
sterke toename van de immunoreactiviteit van A1R zien in het cerebellum van HSV-1 
geïnfecteerde ratten. Deze data wijzen op een up-regulatie van A1R in de vroege fase van 
encephalitis die kan worden gedetecteerd met de A1R antagonist [
11C]MPDX en PET. Zo’n 
up-regulatie zou de release van exciterende neurotransmitters als glutamaat kunnen 
beperken, en de prikkelbaarheid van neuronen in het brein kunnen verminderen, waardoor 
de betrokken neuronen tegen de negatieve gevolgen van overstimulatie worden beschermd. 
 
In hoofdstuk 5 onderzochten we of transiënte opening van de bloed-hersen barrière na 
behandeling van proefdieren met (niet-radioactieve) adenosine A1 en A2A receptor agonisten 
met behulp van hydrofiele radiofarmaca en PET kan worden waargenomen. Zulke tracers 
kunnen de intacte bloed-hersen barrière niet passeren, maar kunnen die wel passeren 
wanneer de barrière is geopend. Voor deze pilotstudie maakten we gebruik van 
[
11
C]CH3-AMD3465 (een CXCR4 antagonist) en [
18
F]AMC15 (een dopamine D2 receptor 
agonist). De hersenopname (SUV) en het distributievolume (VT) van beide tracers waren 
niet verhoogd na voorbehandeling van proefdieren met CPA of Lexiscan. Verder onderzoek 
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is noodzakelijk om vast te stellen of deze negatieve bevinding te wijten is aan een 
ongeschikte kinetiek van de gebruikte radiofarmaca of aan het niet-opengaan van de 
bloed-hersen barrière in verdoofde ratten. 
 
Het proefschrift eindigt met een Engels- en Nederlandstalige samenvatting en een 
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